Logo of neuralplastJournal's HomeManuscript SubmissionAims and ScopeAuthor GuidelinesEditorial BoardHome
Neural Plast. 2011; 2011: 723184.
Published online Sep 5, 2011. doi:  10.1155/2011/723184
PMCID: PMC3167184

GABA Neuron Alterations, Cortical Circuit Dysfunction and Cognitive Deficits in Schizophrenia

Abstract

Schizophrenia is a brain disorder associated with cognitive deficits that severely affect the patients' capacity for daily functioning. Whereas our understanding of its pathophysiology is limited, postmortem studies suggest that schizophrenia is associated with deficits of GABA-mediated synaptic transmission. A major role of GABA-mediated transmission may be producing synchronized network oscillations which are currently hypothesized to be essential for normal cognitive function. Therefore, cognitive deficits in schizophrenia may result from a GABA synapse dysfunction that disturbs neural synchrony. Here, we highlight recent studies further suggesting alterations of GABA transmission and network oscillations in schizophrenia. We also review current models for the mechanisms of GABA-mediated synchronization of neural activity, focusing on parvalbumin-positive GABA neurons, which are altered in schizophrenia and whose function has been strongly linked to the production of neural synchrony. Alterations of GABA signaling that impair gamma oscillations and, as a result, cognitive function suggest paths for novel therapeutic interventions.

1. Introduction

Schizophrenia is a severe brain disorder that afflicts 0.5–1% of the world's population and that is typically first diagnosed in late adolescence or early adulthood. The illness is manifest as disturbances in perception, attention, volition, inferential thinking, fluency and production of language, and the recognition and expression of emotion that lead to substantial impairments in social and occupational functioning. Many affected individuals suffer from comorbid depression, an increased risk of cardiovascular disease, and excessive nicotine, alcohol, and cannabis use.

Three major domains of symptoms define schizophrenia. The first domain is positive or psychotic symptoms that include delusions, false beliefs firmly held in the face of contradictory evidence; perceptual disturbances and hallucinations, which may occur in any sensory modality but are most commonly auditory and experienced as hearing voices distinct from one's own thoughts; abnormalities in form of thought that are usually manifest as loose associations, over-inclusiveness, and/or neologisms; abnormal psychomotor activity that is usually manifest as grossly disorganized behavior, posturing, and/or catatonia. Negative symptoms include asociality (withdrawal or isolation from family and friends), avolition (impaired initiative, motivation, and decision-making), alogia (poverty in the amount or content of speech), and anhedonia (reduced capacity to experience pleasure). The third category of symptoms includes a number of cognitive abnormalities such as disturbances in selective attention, working memory, executive control, episodic memory, language comprehension, and social-emotional processing.

Although positive symptoms are usually the presenting and most striking clinical feature of schizophrenia, disturbances in cognition appear to be the core features of the illness as they are present before the onset of psychosis and are the best predictor of long-term functional outcome for schizophrenia patients [1]. Therefore, functional recovery (e.g., recovery of the capacity to maintain employment) is largely dependent on improving cognitive deficits.

Although schizophrenia was initially characterized over 100 years ago, we still have only a limited understanding of its pathophysiology. Moreover, we lack efficient tools for its treatment or prevention. For example, the multicenter, NIMH-funded Clinical Antipsychotic Trials in Intervention Effectiveness project recently found that newer atypical antipsychotics are not significantly more effective for treating psychosis than older typical antipsychotic medications and showed little benefit for improving cognitive symptoms [2, 3]. These findings highlight the need to develop novel therapeutic interventions for schizophrenia [4, 5].

If functional recovery of patients with schizophrenia depends on improving cognitive deficits, then understanding the neural basis of the normal cognitive operations that are impaired in schizophrenia is crucial to develop new therapies. Interestingly, a number of findings from postmortem brain studies suggest that schizophrenia is associated with deficits of GABA-mediated synaptic transmission [6]. Furthermore, current hypotheses from cellular and systems neurophysiology suggest that a major role of GABA-mediated transmission is to produce synchronized neural network oscillations [7, 8] which by facilitating the processing and flow of information within and between brain regions may be essential for normal cognitive function [9]. Here we review convergent findings from schizophrenia research, cellular neurophysiology, and cognitive neuroscience that favor the hypothesis that deficits of cognitive function in schizophrenia result from a dysfunction in GABA-mediated synaptic inhibition that disturbs oscillatory neural synchrony.

This paper reviews recent evidence further indicating that in subjects with schizophrenia cognitive dysfunction is associated with alterations of oscillations in the gamma frequency band (30–80 Hz), which are normally induced during tasks that engage cognition [10]. In addition, it reviews the cellular and molecular machinery involved in GABA-mediated synaptic transmission and the mechanisms by which GABA-mediated inhibition may synchronize neural activity in cortical circuits, focusing on the role of parvalbumin- (PV-) positive GABA neurons, whose function has been increasingly linked to the production of synchronized gamma oscillations. Furthermore, data on the postnatal development of PV GABA neurons and their synaptic connections and the developmental trajectories of gene products involved in GABA-mediated synaptic inhibition is reviewed. Finally, recent studies further suggesting that schizophrenia is associated with alterations in GABA-mediated synaptic transmission, particularly, but not exclusively, from PV neurons are highlighted. Alterations of GABA signaling that impair gamma oscillations and therefore cognitive function in schizophrenia suggest potential paths for therapeutic interventions.

2. Altered Neural Synchrony and CognitiveFunction in Schizophrenia

Schizophrenia is associated with deficits in behavioral tasks that assess perceptual and cognitive processes [10, 11]. Many such tasks normally increase synchronized oscillatory activity as measured in the electroencephalogram (EEG), and such increase in synchrony is altered in subjects with schizophrenia [11, 12]. For example, gamma-band synchrony during tasks that require visual gestalt perception is attenuated in schizophrenia patients [13]. One of the core cognitive deficits in schizophrenia is a dysfunction of working memory, a system to keep information in mind and to manipulate it while performing complex tasks [14]. Gamma oscillatory activity (30–80 Hz) may play an important role in normal working memory, given that gamma band synchrony increases with increasing working memory load [15, 16]. In patients with schizophrenia, working memory deficits are accompanied by altered patterns of cortical oscillatory activity [11], since schizophrenia patients actually fail to enhance gamma activity with increasing working memory load [16] and show overall increased gamma band power during working memory [16, 17]. Subjects with schizophrenia also have decreased oscillations in various frequency bands during specific phases of the working memory process, including encoding, maintenance, and retrieval [18].

Cognitive function, including working memory, implicates an interconnected network of brain regions, many of which show structural and functional abnormalities in schizophrenia [19]. The prefrontal cortex (PFC), which is extensively interconnected with cortical and subcortical regions, is thought to exert top-down control of the flow of neural activity between brain regions to provide cognitive control, coordinating incoming sensory and motor information with representations of internal goals and rules to select a context-appropriate behavioral response [20]. Subjects with schizophrenia have significant deficits in cognitive control [10] and attenuated gamma oscillations in PFC during cognitive control tasks [21]. Cognitive control-related gamma activity, but not theta activity, is reduced in the frontal cortex of first-episode schizophrenia patients independent of medication status, suggesting a deficit related to the disease process as opposed to medication side effects or the consequences of being chronically ill [22]. Interestingly, some studies reported a positive correlation between gamma oscillations and hallucination symptoms score in schizophrenia [23, 24], indicating that the propensity for auditory hallucinations correlates with an increased tendency to enter states of oscillatory synchrony [24]. It remains to be determined whether the decrease in gamma activity associated with cognitive deficits and the positive correlation between gamma activity and psychotic symptoms are due to different underlying mechanisms, manners of eliciting gamma, or cohorts of subjects.

If, as suggested by multiple lines of evidence, altered neural synchrony underlies impairment of cognition in schizophrenia, then understanding the neural mechanisms normally involved in production of synchronized oscillations in neocortical circuits is crucial to develop new therapeutic interventions. Whereas several mechanisms have been proposed, production of rhythms via GABA-mediated inhibition is currently a leading candidate mechanism, as reviewed in the following.

3. Basic Mechanisms of GABA-Mediated Fast Synaptic Transmission

By definition, GABA neurons have the capacity to synthesize GABA from glutamate via the enzymatic activity of glutamic acid decarboxylase (GAD), for which there are two gene products of different molecular weight, GAD65 and GAD67 [25]. Whereas the GAD isoforms differ in a number of properties, their specific functional roles are not fully understood [25]. Interestingly, GAD65 and GAD67 are differentially expressed in GABAergic terminals in a cell type-specific manner (see below).

GAD-mediated GABA synthesis occurs in the cytosol, and GABA is transported into synaptic vesicles by the vesicular GABA transporter vGAT (Figure 1). Shortly after an action potential arrives at the nerve terminal, vesicular GABA release is triggered with a certain probability and in a Ca2+-dependent manner. In PV neuron terminals, PV may act as a Ca2+ buffer that binds residual Ca2+ after activation of the Ca2+ sensor that triggers vesicular GABA release. At all synaptic connections from cortical GABA neurons thus far studied, the effects of synaptically released GABA are mediated by GABAA receptors (GABAARs), as the postsynaptic response is abolished by GABAAR antagonists in hippocampus [2633] and neocortex [3441]. In contrast, GABAB receptors mediate the postsynaptic effects of GABA only at connections from GABA neurons of the neurogliaform cell subtype [42].

Figure 1
Scheme showing a nerve terminal from a parvalbumin- (PV-) positive GABA neuron shortly after an action potential triggered Ca2+-dependent GABA release, highlighting components currently hypothesized to be altered in schizophrenia. In PV terminals, GABA ...

Postsynaptic GABAARs are heteropentamers composed of subunits from 7 different families (α1–6, β1–3, γ1–3, δ, ε, θ, and ρ1–3) typically combined following a 2α : 2β : γ stoichiometry to form a GABA-activated chloride channel [43, 44]. Importantly, the subunit composition of the GABAAR complex determines many of its functional properties. For instance, GABA-activated chloride currents produced by α1 subunit-containing GABAARs (α1-GABAARs) have much faster decay kinetics than currents mediated by GABAARs containing other α subunits [43].

The subunit composition also determines important pharmacological properties of the GABAARs. Benzodiazepines bind to GABAARs via a binding site localized at the interface between α and γ subunits [45, 46] and may modulate (potentiate or decrease) GABAAR function in an α subunit-selective manner [47]. For example, zolpidem enhances GABA effects preferentially at α1-GABAARs, whereas the α3IA and α5IA compounds are inverse agonists preferentially at α3-GABAARs and α5-GABAARs, respectively [47]. Other drugs, including TPA023 (also named MK0777), TPA023B, TPA123, and TPA003 have comparable binding affinity at α1-, α2-, α3-, and α5-GABAARs but may lack pharmacological effects at certain GABAAR subtypes. In particular, TPA023 is a partial agonist at α2- and α3-GABAARs but has no agonist efficacy at α1- and α5-GABAARs [48].

The magnitude and direction of the ionic current flowing through GABAARs depends on its driving force or difference between its electrochemical equilibrium potential (EGABAA) and the resting membrane potential (Vmr) in the plasma membrane compartment where GABAARs are located [49]. Because GABAAR channels are largely permeable to chloride, EGABAA is close to the chloride equilibrium potential (ECl) and therefore EGABAA depends on the sodium-potassium-chloride cotransporter 1 (NKCC1) and the potassium-chloride co-transporter 2 (KCC2), which mediate chloride uptake and extrusion, respectively [43]. Importantly, since the active GABAAR conductance tends to “clamp” the membrane potential at EGABAA [49], if EGABAA is negative relative to Vmr  (Vmr > EGABAA), the GABAAR currents are hyperpolarizing, whereas if EGABAA is positive to Vmr  (EGABAA > Vmr), the GABAAR currents produce depolarization. Commonly, EGABAA is negative to Vmr, however, in certain cell types or subcellular compartments (and in general, early in brain development) EGABAA > Vmr [43].

Whether the GABAAR conductance has inhibitory or excitatory effects depends on the relation between EGABAA and the voltage threshold for action potential firing (Vth), which is always depolarized relative to Vmr  (Vth > Vmr). When Vth > Vmr > EGABAA, the chloride current is hyperpolarizing and clearly inhibitory because it shifts the membrane potential away from firing threshold, thus reducing the probability of firing. In contrast, if EGABAA > Vth > Vmr, the chloride current is excitatory because it tends to depolarize the membrane above Vth. However, if Vth > EGABAA > Vmr, the GABAAR conductance is inhibitory because, even though EGABAA > Vmr, shunting by the active GABAAR conductance keeps the membrane potential below firing threshold. Importantly, GABAAR-mediated inputs that depolarize the membrane below Vth  (Vth > EGABAA > Vmr) can have dual, time-dependent inhibitory/excitatory effects. Initially, when the GABAAR conductance is active, the net effect of the synaptic input is inhibitory because of the shunting effect [50]. However, the depolarizing postsynaptic potential outlasts the duration of the GABAAR conductance, thus increasing the firing probability once the GABAAR conductance decays [50]. Importantly, the depolarizing GABAAR-mediated post-synaptic potential may be amplified by voltage-dependent Na+ currents localized perisomatically, possibly in the initial segment of the axon [51, 52], enhancing its excitatory effect. The inhibitory versus excitatory effect of the GABAAR conductance may be dynamic, because Vmr and Vth are subject to modulation and change over time. In addition, EGABAA may vary between cell types and subcellular compartments, depending on the NKCC1/KCC2 activity ratio [43].

It has been commonly suggested that uptake of extracellular GABA by plasma membrane transporters could help terminate the synaptic effect of GABA and thus the duration of the inhibitory postsynaptic current (IPSC). In the CNS, GABA uptake is largely mediated by the plasma membrane GABA transporter 1 (GAT1) which translocates GABA through the neuronal and glial membrane (Figure 1). Interestingly, recent experiments indicate that GAT1 does not control the time course of GABAAR-mediated IPSCs, since the duration of IPSCs produced at single synapses is not affected by pharmacological inhibition of GAT1, nor in GAT1 knockout mice [5356]. The finding that GAT1 does not control IPSC duration may be explained by GAT1's predominantly extrasynaptic localization [5762] and by the slow GAT1-mediated GABA translocation rate [63, 64] compared with the rapid GABAAR activation by synaptic GABA [43]. Other experiments suggest that GAT1's main role is preventing intersynaptic GABA spillover [53, 56], (e.g., the unintended activation of GABAARs at a given synapse by GABA released at adjacent synapses). Four different GABA transporters have been cloned: GAT1, GAT2, GAT3, and BGT1 [65]; therefore, it is possible that some of the GABA transporters different from GAT1 have properties consistent with uptake-mediated control of IPSC duration. However, GAT2 is only found during very early brain development and BGT1 is not abundant in brain [65]. GAT3 is mostly localized in glia, and the effects of GAT3 blockade indicate that, similar to GAT1, GAT3's main role is reducing the effects of GABA spillover [66].

4. Mechanisms of GABAAR-Mediated-Gamma- Band Synchronization

The mechanisms by which GABAAR-mediated inhibition may synchronize postsynaptic cell activity have been reviewed in detail previously [7, 8, 67, 68]. Figure 2 illustrates a group of pyramidal neurons firing asynchronously in response to some excitatory inputs that receive common GABAAR-mediated hyperpolarizing inhibition. If such GABA-mediated hyperpolarizing input is strong enough, then the postsynaptic neurons will be inhibited together during a certain time window and, as the GABAAR inhibitory effect decays, will escape from inhibition to resume firing nearly in synchrony (Figure 2). Such postinhibition synchronous spiking of pyramidal cells can be elicited by single-GABA neurons [28] and readily generates synchrony throughout large numbers of neurons in computational network models [7, 67]. Therefore, post-inhibition synchronous spiking is a strong candidate mechanism for production of neural synchrony. Alternative synchronization mechanisms, which are not reviewed here, involve gap junctions connecting pyramidal cell axons [8] or noisy but correlated inputs [69].

Figure 2
A model for GABAAR-mediated synchronization mechanisms. The left panel shows a group of pyramidal cells that are common postsynaptic targets of an inhibitory GABA neuron. Perisomatic-targeting GABA neurons such as that in the scheme produce stronger inhibition ...

Importantly, neuronal synchrony is commonly observed during episodes of rhythmic/oscillatory network activity, especially in association with cognitive tasks [70, 71]. Therefore, the circuit mechanisms of synchronized oscillations via GABAAR-mediated inhibition must involve rhythmic interneuron firing and trains of IPSCs in their postsynaptic target cells. As multiple subclasses of GABA neurons exist [72], a crucial issue is whether specific subtypes are involved in the mechanisms of synchronized oscillations. Synchronized oscillations occur at different frequency bands [70], including theta (~4–10 Hz), beta (~15–30 Hz), and gamma (~30–80 Hz). Whether oscillations of all frequency bands depend on GABAAR-mediated inhibition and, if so, on particular GABA neuron subtypes is still a matter of investigation [73]. Here we focus on models for the mechanisms of gamma oscillations, which are commonly induced during cognitive tasks and seem to be impaired in the cortex of patients with schizophrenia.

Synchronization by the GABAAR-mediated mechanism described in Figure 2 requires sufficiently strong GABA synapses activating a relatively large GABAA conductance via inhibitory inputs localized near the site of action potential initiation. In pyramidal cells, action potentials are commonly triggered near the axon initial segment (AIS), the axonal compartment that is closest to the soma [74]. Therefore, inhibitory inputs onto the perisomatic membrane compartment (soma, proximal dendrites, and AIS) produce stronger inhibition than inputs onto distal dendrites [75, 76], suggesting that perisomatic-targeting GABA neurons may be crucially involved in production of synchronized oscillations. Three main subtypes of perisomatic-targeting GABA neurons exist in neocortex and hippocampus, namely, the parvalbumin-positive and the cholecystokinin-positive basket cells (PVBCs and CCKBCs) and the PV-positive chandelier cells (PVChCs). Both PVBCs and CCKBCs innervate pyramidal cells at the soma and proximal dendrites (Figure 3), whereas PVChCs synapse exclusively onto the AIS (Figure 3). Because a synaptic GABAAR conductance has stronger inhibitory effect the closest it is localized to the site of spike initiation [50], PVChC inputs onto the AIS are predicted to have the strongest inhibitory power.

Figure 3
Diversity of perisomatic-targeting GABA neuron-mediated inhibition in cortical circuits may be due to differences in the reversal potential for the GABAA-mediated current. (a) The scheme illustrates targeting by basket cells (either parvalbumin- or cholechystokinin-positive), ...

Surprisingly, some recent studies suggested that synaptic input from PVChCs is actually excitatory, since stimulation of PVChCs frequently initiates spikes in postsynaptic pyramidal cells via GABAAR activation [40]. In addition, electron microscopy studies support the idea that PVChC inputs are excitatory, as they show very low levels of KCC2 in the AIS compared to the soma or dendrites [40, 77]. Since KCC2 extrudes chloride, lower AIS levels of KCC2 should produce a more positive EGABAA, resulting in a depolarizing GABAAR current (Figure 3) [43]. In fact, in paired recordings using experimental conditions that preserve the physiological intracellular chloride concentration, PVChC inputs depolarize the postsynaptic pyramidal neurons [40, 78], whereas in identical experimental conditions PVBC inputs are hyperpolarizing [40, 78], consistent with higher levels of KCC2 transporters in the somatic membrane [40, 77]. Experiments with uncaging of GABA onto GABAARs in specific membrane compartments similarly showed a more depolarized EGABAA at the AIS compared with the soma and dendrites [79].

An excitatory depolarizing GABAAR-mediated input by PVChCs is inconsistent with their participation in inhibition-based synchronization. However, although EGABAA at the AIS is 10–20 mV depolarized before Vmr, it may be negative relative to Vth [40, 78, 79]. As highlighted above, when Vth > EGABAA > Vmr, the GABAA conductance has a dual inhibitory/excitatory effect (Figure 3), which in the case of PVChC inputs may be amplified by their proximity to the spike initiation site. Such inhibitory/excitatory effect may contribute to synchronization of postsynaptic cell activity at gamma band frequency [7, 80]. Specifically, since the postsynaptic potential outlasts the duration of the GABAAR conductance (Figure 3), once the conductance is deactivated, the depolarizing postsynaptic potential accelerates the post-inhibition synchronous spiking, facilitating synchronization at gamma frequency. Such a mechanism operates at GABAAR-mediated synapses onto GABA neurons [7, 80] and could also apply at PVChC inputs onto pyramidal neurons.

The depolarizing effect of PVChCs described in neocortex [40, 78] contrasts with pioneer paired recording experiments showing that either PVBC or PVChC inputs hyperpolarize hippocampal pyramidal neurons [26]. A hyperpolarizing effect of hippocampal PVBCs and PVChCs was also suggested recently by experiments using conditions that preserve the intracellular chloride concentrations [81], but that are different from the intracellular chloride-preserving conditions employed in studies of neocortical PVChC inputs [40, 78]. Interestingly, the AIS membrane has low levels of KCC2 in neocortical [40] and hippocampal [77] pyramidal cells. The discrepancies between findings for hippocampal versus neocortical PVChCs highlight the need for further research to clarify the enigmatic role of this class of GABA neurons [82]. Whether excitatory or inhibitory, the unique properties of PVChC inputs suggest that the reported alterations of these cells must significantly contribute to cortical circuit dysfunction in schizophrenia [83].

In contrast to PVChCs, both PVBC and CCKBC inputs are hyperpolarizing (Vmr > EGABAA), although EGABAA is slightly, but significantly, different for PVBC versus CCKBC inputs [84]. Such differences in EGABAA were attributed to the activity of the voltage- and chloride-dependent chloride channel ClC-2, which helps maintaining a low internal chloride concentration (thus a hyperpolarized EGABAA) at inputs from PVBCs but not from CCKBCs [84]. The ClC-2-dependent regulation of internal chloride at PVBC inputs is dependent on the extent of GABAAR activation [84]. These findings highlight a degree of functional diversity between BC subtypes, showing that PVBC inputs, but not CCKBC inputs, possess a mechanism to prevent internal chloride accumulation during high-frequency neuronal activity such as that observed in GABA neurons participating in gamma oscillations.

Functional diversity between PVBCs, PVChCs and CCKBCs is also suggested by recent data demonstrating that the relative levels of GAD65 and GAD67 proteins in nerve terminals of these cells vary significantly in a cell-type-specific manner [85]. Using immunocytochemical labeling combined with a quantitative fluorescence microscopy methodology [86], the colocalization of GAD65 and GAD67 proteins in the same terminals was assessed for PVBCs, PVChCs and CCKBCs (Figure 4). The latter cells were identified using an antibody that detects the cannabinoid 1 receptors expressed by inhibitory terminals. Importantly, in the prefrontal cortex nearly all cannabinoid 1 receptor-expressing cells detected using this antibody are immunoreactive for CCK [87]. This assessment showed that the ratio of GAD67/GAD65 expression varied significantly across each type of terminal, with very high (15.42) and very low (0.18) ratios observed in terminals of PVChCs and CCKBCs, respectively, and a ratio of 1.49 for PVBC terminals [85]. These data reinforce the idea that synaptic connections from different perisomatic-targeting GABA neuron subtypes are functionally diverse. The impact of different GAD67/GAD65 ratio on the properties of the GABA synapses studied remains enigmatic because the differential functional roles of GAD67 and GAD65 are still poorly understood. In mice, GAD67 deficiency produces major alterations, as GAD67−/− animals are born with cleft palate (which is lethal) and with ~90% reduction of bulk GABA concentration in brain tissue [88, 89]. In contrast, GAD65−/− mice survive into adulthood, displaying ~20% reduction in total brain GABA concentration [90] together with increased susceptibility to seizures [90, 91], increased anxiety [92], and altered fear conditioning [93]. In synapses of GAD65−/− mice, GABAAR-mediated synaptic transmission appears normal during low-frequency stimulation but is strongly impaired at stimulation frequency of 30 Hz or higher [94, 95]. In mice with cerebellum-specific GAD67 deficiency [96], GABAAR-mediated transmission is markedly weaker even at low stimulus frequency [96], suggesting a crucial role of GAD67 in baseline synaptic transmission. Whether the effects of GAD67 deficiency on cerebellar synapses are observed in cortical synapses as well remains to be determined. Importantly, GAD67 deficiency markedly impairs the maturation of cortical GABAergic synaptic connections [97]. Therefore, testing the role of GAD67 in synaptic transmission independent of its role in synapse development requires a paradigm in which GAD67 is decreased once GABA synapse maturation has been completed. In addition, GAD65 and GAD67 both comprise ~50% of total GAD protein in mouse cortex, while GAD65 comprises ~70% in the rat cortex [98]. The GAD65 and GAD67 proportions of the total GAD protein in human cortex is unknown; however, the differences between mouse and rat strongly stress the need to study GAD function in molecularly relevant systems when trying to understand their roles in human disease.

Figure 4
Relative levels of GAD65 and GAD67 in PVCh, PVBC, and CCKBC terminals. Cryostat sections of monkey PFC tissue (40 μm thick) were quadruple labeled for GAD65, GAD67, PV, and cannabinoid receptor 1 (CB1r). Among inhibitory synaptic boutons, ...

GABAAR-mediated inputs involved in gamma band synchronization must inhibit their postsynaptic neurons for a time compatible with the gamma oscillation period. For instance, long-lasting postsynaptic currents such as those activated by GABAB receptors (which may last hundreds of milliseconds) are inconsistent with gamma synchrony, as postsynaptic neuron inhibition would be longer than the typical gamma cycle period. Whereas all GABAAR subtypes produce faster currents than GABAB receptors, the GABAA current duration depends on the subunit composition [43, 99]. As mentioned, recombinant α1-GABAARs produce currents with the fastest decay [100]. Therefore, PVBCs may produce IPSCs with faster decay, as α1-GABAARs predominate at inputs from PVBCs [33, 41, 101, 102] whereas α2-GABAARs predominate at both PVChC and CCKBC inputs [41, 101103]. Interestingly, PVBCs, CCKBCs, and PVChCs elicit in pyramidal cells uIPSCs with nearly identical kinetics [39, 104107]. Therefore, in addition to the GABAAR subunit composition, the IPSC kinetics are determined by additional factors that may not affect recombinant GABAARs. Such factors include GABAAR subunit phosphorylation and other posttranslational modifications [108, 109], and the time course of the GABA concentration transient to which GABAARs are exposed [41].

Although PVBCs and CCKBCs produce IPSCs with similar duration during individual GABA release events, CCKBCs distinctively produce multiple asynchronous release events after single-action potentials [104]. Multiple GABA release events may prolong the postsynaptic inhibitory effect of each CCKBC spike [104]. In contrast, PVBC terminals produce a single synchronous GABA release event per presynaptic action potential [104, 110]. Asynchronous release from CCKBC terminals has been observed in multiple studies [104, 107, 111115] suggesting that it is a fundamental property that prolongs the inhibitory effect of CCKBCs on postsynaptic neurons possibly linking their activity with synchronization at frequency bands lower than gamma.

The data reviewed above suggest that, relative to CCKBCs and PVChCs, PVBCs have unique properties consistent with a crucial role in the mechanisms of gamma band synchrony. However, such data do not directly assess involvement of any of these GABA neuron subtypes in the gamma oscillation mechanisms. Interestingly, some electrophysiological studies more directly indicate that among perisomatic-targeting GABA neuron subtypes, PVBCs are most likely to be involved in the production of gamma oscillations. For instance, whereas both BCs and ChCs are active during gamma oscillations in vivo [116118] and in vitro [119124], the firing of CCKBCs and PVChCs is more weakly coupled with the gamma oscillation cycle than PVBC firing [124], although CCKBC and PVChC firing is strongly coupled with theta oscillations [125127]. Furthermore, gamma oscillations are significantly reduced or abolished by suppressing PV cell activity with optogenetic methods that do not directly affect CCKBCs [128] or by stimulation of presynaptic opioid receptors that suppress GABA release from PVBCs but not from CCKBCs or ChCs [124]. Therefore, perisomatic GABAAR-mediated currents from PVBCs appear to be the main source of GABAAR-mediated synchronization in the gamma frequency band.

Essential for modeling the circuit mechanisms of gamma synchronization is to understand how PVBCs are normally recruited to fire rhythmically at gamma frequency. Recruitment of PVBC firing depends on activation of not only excitatory but also inhibitory synaptic inputs onto them since PVBCs target other GABA neurons, including nearby PVBCs [129, 130], and are also inhibited by inputs from different classes of GABA neurons, including the CCKBCs [112]. Gamma oscillations are successfully generated in computational model networks that rely on reciprocal inhibition between GABA neurons and are thus called ING, for Interneuron Network Gamma [131133]. In ING models, GABA neurons are recruited by a strong tonic excitation that drives them to fire at a frequency above gamma, and the reciprocal inhibition synchronizes GABA neuron firing at a frequency inversely related to the IPSC duration, falling within gamma range for durations typical of α1-GABAAR-mediated IPSCs [132, 133]. Whereas gamma rhythms possibly induced by ING-like mechanisms have been observed experimentally [134], the actual source of the strong tonic excitation onto GABA neurons required by ING models is unclear. Metabotropic glutamate receptors [67, 134] or kainate receptors [135] could provide such a tonic drive, although this possibility is supported, only indirectly, by findings obtained with AMPA- and NMDA-mediated synaptic transmission blocked. A recent study employing genetically engineered mice with a deletion of GABAAR expression in PVBCs [136] directly tested whether inhibition onto PVBCs is necessary to generate gamma oscillations, as predicted by the ING models. In such mice, GABAAR-mediated IPSCs were abolished exclusively in PVBCs [136] and theta oscillations and their coupling with gamma oscillations were severely disrupted [136]. However, in such mice hippocampal gamma oscillations in vivo were intact as compared with wild-type mice [136]. These data argue against the ING model for gamma band synchrony and suggest that inhibition onto PVBCs, potentially from CCKBCs [112], is crucial for coupling theta and gamma oscillations. Such theta-gamma coupling is thought to be important for cognitive function [137].

As the role of ING mechanisms in gamma oscillation production continues to be tested, some studies favor an alternative model, known as Pyramidal Interneuron Network Gamma (PING), which depends on recurrent excitatory-inhibitory synaptic interactions. In PING, PVBCs are recruited by phasic glutamate-mediated inputs from the pyramidal cells, and the PVBCs provide strong feedback inhibition that synchronizes pyramidal cell firing [67, 121, 138]. The PING model predicts that during the gamma oscillation cycle PVBCs fire after the pyramidal neurons, with timing consistent with monosynaptic recruitment by pyramidal cells [138]. The spike timing of pyramidal cells and putative BCs during gamma oscillations in awake behaving animals is actually consistent with the PING model, as BCs fire 2-3 ms later than pyramidal neurons [139, 140]. Similar findings were obtained for pyramidal and PVBC spikes during gamma oscillations in hippocampal and neocortical brain slices [119, 120, 122, 123, 141]. PING models also predict the presence of trains of gamma frequency IPSCs in pyramidal neurons and trains of gamma frequency EPSCs in PVBCs [67]. Evidence consistent with IPSC trains in pyramidal cells was obtained for gamma oscillations in vivo [117, 142] and in vitro [119123, 141, 142]. In addition, during gamma oscillations in vitro, PVBCs display rhythmic EPSCs highly synchronized with the gamma rhythm [120122]. Interestingly, optogenetics experiments show that driving PV neurons by nonrhythmic excitatory inputs is sufficient to generate gamma synchrony via feedback inhibition [128], a finding also consistent with the PING model of gamma.

PING mechanisms rely on recruitment of PVBCs by phasic excitatory input [138]; therefore, the properties of glutamate synapses onto PV neurons are extremely relevant for models of gamma oscillations. Interestingly, schizophrenia has been hypothesized to be associated with a deficit of glutamate transmission [143], more specifically with hypofunction of NMDA receptors, particularly in GABA neurons [143]. Moreover, some studies have suggested that NMDA hypofunction could especially affect PV cells [144146]. Therefore, an important question is the following: what are the subtypes of glutamate receptors that mediate synaptic activation of PV GABA neurons? The answer to this question is relevant in the context of alterations of gamma synchrony in schizophrenia, because if NMDA receptors are important to recruit PV neurons in a PING mechanism of gamma, then NMDA hypofunction could be linked to deficits of gamma synchrony in schizophrenia. Data from recent studies showed that systemic administration of NMDA receptor antagonists increase the firing rate of putative pyramidal neurons and decrease the firing of putative inhibitory cells in the PFC in vivo [147], suggesting that NMDA receptors may be crucial to recruit inhibition. An important question not directly addressed by such studies [147] is whether the inhibitory neurons dependent on NMDA receptors belong to the PV-positive class of GABA neurons. Whereas several studies demonstrated that synaptic excitation of PV neurons is relatively NMDA receptor independent, until recently no studies directly compared the importance of NMDA receptors in synaptically evoked recruitment of PVBCs versus pyramidal neurons in neocortical circuits. Recent data from recordings in mouse PFC show that, compared with pyramidal cells, glutamate synapses onto PVBCs have EPSCs with faster decay and weaker NMDA receptor contribution [148], supporting the idea that the rapid activation of PVBCs [149] is largely dependent on fast AMPA receptor-mediated excitation. Moreover, in a computational model producing gamma oscillations via PING mechanisms, fast AMPA-mediated excitation of PVBCs was critical for gamma band synchronization because the slower decay time course of NMDA-mediated EPSCs disrupted gamma band synchrony [148]. Some studies indeed showed that gamma oscillations are not affected or are enhanced by NMDA receptor antagonists, whereas AMPA receptor antagonism completely abolished them [150153]. Similarly, in mice with AMPA receptor deletion genetically engineered to occur exclusively in PV-positive neurons, gamma oscillations are strongly reduced [154]; however, NMDA receptor deletion selectively in PV-positive cells does not decrease and in fact increases gamma oscillation power [155]. The results of recent studies therefore suggest that, in mature cortical circuits, NMDA receptors only play a minor role in synaptically evoked excitation of PV-positive neurons and therefore on gamma oscillations produced via PING mechanisms. If indeed PV neuron excitation is normally weakly dependent on NMDA receptors, then such data suggest that excitatory synapses onto PV cells are an unlikely target of NMDA receptor hypofunction mechanisms in schizophrenia. Importantly, although in most cases gamma synchrony is unaffected by NMDA receptor blockade, the effects of NMDA receptor antagonists on gamma oscillations may vary with cortical region or layer, in some cases ketamine producing a decrease, in others producing an increase in gamma power [152, 156]. In addition, some data show that whereas mature PVBCs display a relatively small NMDA receptor mediated component in synaptic responses [148, 157, 158], such NMDA component is substantially more prominent in immature PVBCs [157, 158]. Such findings suggest the interesting possibility that alterations of NMDA receptor-signaling during early brain development could alter PVBC function in ways that persist into adulthood, thus changing the role of PVBCs in mature local circuits. Interestingly, a recent study showed that a genetically engineered deletion of NMDA receptors from PV-positive cells does not have significant effects if the deletion is produced in the brain of adult mice [159]. However, a similar deletion produced during early brain development caused behavioral alterations in adult mice, some of which resemble behavioral dysfunction in patients with schizophrenia [159].

5. Postnatal Development of GABA-Mediated Synaptic Inhibition

Schizophrenia is hypothesized to be a neurodevelopmental disorder based on data linking the disease with adverse events during pre- and perinatal periods and the presence of cognitive and behavioral deficits in childhood many years prior to the onset of psychosis during late adolescence and early adulthood [160]. Adolescence, the developmental transition from parent-dependent childhood to independent adulthood, is associated with significant changes in behavior and with marked improvements in cognitive control [161]. Moreover, gamma band synchrony emerges during childhood and continues to mature until early adulthood [162, 163]. The postnatal developmental trajectory of GABA-synaptic function may therefore suggest critical periods of vulnerability during which the mechanisms producing neural synchrony could become dysfunctional in schizophrenia. In what follows we review developmental studies of the functional properties of PVBCs and their synaptic connections in rodents and of GABA-related gene products studied in the human and nonhuman primate brain.

Mature PV neurons have a unique fast-spiking (FS) firing pattern (Figure 5), which includes very narrow action potentials and high frequency firing without the spike-frequency adaptation typically observed in pyramidal cells and other GABA neuron subtypes [72]. Although the nonadapting properties of FS cells are revealed with artificial stimuli (rectangular currents steps lasting several hundred ms), they correlate strongly with the particular ability of FS cells to respond to oscillatory inputs at gamma frequency (Figure 5), which is likely due to the gamma frequency resonance of the FS cell membrane [164]. Immature FS neurons, in contrast, have significantly slower action potentials and stronger spike-frequency adaptation, fail to respond efficiently to gamma frequency oscillatory inputs, and show much slower conduction velocity of action potentials along their axon [33, 165167]. In rodent hippocampus, as well as in auditory, somatosensory, and prefrontal cortices, maturation of FS neuron electrical properties is complete by postnatal day 25 (P25) after which FS neurons display adult-like electrical properties [33, 157, 165167].

Figure 5
Intrinsic electrical properties of parvalbumin-positive GABA neurons. (a) Single action potentials in fast-spiking PV-positive neurons (FS) have significantly faster duration than pyramidal cell (PC) spikes or spikes in many other GABA neuron subtypes ...

Functional properties of the inhibitory connections onto excitatory neurons also differ markedly between developing and mature PVBCs: unitary IPSCs (uIPSCs), from immature PVBCs, are weaker and have slower decay time than uIPSCs produced by mature PVBCs [33, 168]. Such acceleration of uIPSC decay is explained by an increase in the contribution of α1-GABAARs with maturation [33]. A GABAAR subunit switch may also contribute to the developmental acceleration of the uIPSP decay [167] although developmental changes in the pyramidal cell membrane time constant contribute as well [167]. Mature FSBCs produce highly synchronous GABA release, in contrast to asynchronous release from mature CCKBCs [33, 104, 110]. However, GABA release is less synchronous and less reliable in synapses from immature FSBCs [33]. Postnatal maturation of the FSBC connections takes place relatively rapidly, as uIPSCs acquire mature properties by P28 [33, 167].

Inhibition onto FS cells also undergoes significant developmental changes. For example, uIPSCs at FSBC-to-FSBC connections mature within 3-4 weeks postnatally [33], whereas miniature IPSCs (mIPSCs, which represent GABA release at single synapses) recorded from FSBCs acquire adult-like properties by P25 [165]. Unitary EPSPs (uEPSPs) at immature pyramidal cell-to-FSBC connections have slow decay time, which accelerates markedly during development, reaching adult-like values by ~P22 [167]. Similarly, miniature EPSCs (mEPSCs) recorded from immature FSBCs are slow and show a developmental acceleration of their decay to reach very fast mEPSC decay values in mature FS cells [148, 157, 158, 165]. Fast-decaying EPSCs and EPSPs in mature FSBCs are largely mediated by AMPA receptors [148, 157, 158, 167, 169], suggesting that the rapid EPSC decay in FSBCs is due, at least in part, to a weak contribution from the slow-decaying NMDA currents [148, 157]. Actually, the developmental acceleration of EPSC decay is accompanied by a marked decrease in the contribution of NMDA currents which is still ongoing at ~P40 to ~P96 [157], which in rodents corresponds to the transition from adolescence to adulthood [170]. In contrast to PFC, in hippocampus, auditory, and somatosensory cortices, NMDA receptor contribution in FSBCs decreases prior to adolescence [167, 169, 171, 172].

Although the mechanisms controlling postnatal development of PVBC firing properties and their synaptic inputs and outputs are important candidates as the substrate of alterations in schizophrenia, they are still poorly understood. Neuregulin-1 is a trophic factor crucial for brain development that is encoded by a schizophrenia susceptibility gene and is highly expressed during late developmental periods and in adulthood [173, 174]. Among various neuregulin-1 receptors, the ErbB4 receptor, whose gene also confers schizophrenia susceptibility [173, 174], is enriched in GABA neurons, particularly in PV-positive cells [175, 176] where it facilitates GABA release [176], possibly mediating neuregulin-1 enhancement of gamma oscillations [177]. Neuregulin-1 signaling appears to regulate early development of GABA synapses [178] and, via ErbB4 receptors, may control development of PV neuron synapses [179]. Interestingly, ErbB4-mediated neuregulin-1 effects are crucial for development of excitatory synapses onto PVBCs [179, 180].

In parallel to the maturation of their firing pattern and synaptic connections, PVBCs undergo significant developmental morphological changes. For instance, the total length of the dendritic and axonal trees of PVBCs increases significantly from P6 to P25 [33], the number of axonal branch points increasing five times during this developmental period [33]. The number of postsynaptic neurons innervated by individual PVBCs also increases markedly with postnatal development [97], resulting in a higher functional connectivity between mature PVBCs and excitatory neurons [33]. A crucial factor regulating development of innervation patterns by PVBCs is GAD67-mediated GABA synthesis [97]. For instance, GAD67 knockdown in single PVBCs dramatically decreases formation of axon branches and synapses, as well as the number of postsynaptic neurons innervated by each PVBC [97]. Such effects of GAD67 knock-down are observed in organotypic cell cultures and in the primary visual cortex in vivo with GAD67 knock-down induced at P13 and the patterns of innervation examined at P20 or P32 [97]. The role of GAD67-mediated GABA synthesis in formation and/or stability of PVBC synapses may involve neuroligin-neurexin interactions and modulation of GABA receptor trafficking [181].

Because detailed molecular and biophysical analysis of developmental changes in GABA neuron and GABA synapse function is feasible only using animal models, especially rodents, an important question is how developmental time scales translate from animal to human brain [182]. Proper translation would require understanding if similar developmental stages are found in rodent and human brains, whether such developmental stages involve similar processes and underlying mechanisms, and whether developmental periods cover similar fractions of the total lifespan. Some developmental changes, for instance, excitatory synapse pruning, have similar proportional duration, with only the extent of synaptic pruning differing across mammalian species [183]. Also, functional maturation of glutamate synapses onto pyramidal cells occurs prior to adolescence in nonhuman primates [184], and in rodents [185191].

Whereas some unique studies have assessed functional properties of PVBCs and PVChCs in the cortex of adult humans [40, 192, 193] and nonhuman primates [39, 184, 194197], we lack information on the developmental trajectory of synaptic inhibition from primate PV neurons. Interestingly, functional properties of yet unidentified GABA synapses onto primate pyramidal neurons change during development through adolescence in a manner consistent with changes in the expression of gene products involved in GABA-mediated transmission [198]. Specifically, the decay time of GABAAR-mediated synaptic potentials accelerates during adolescence in parallel to changes in the protein and/or mRNA levels for α1 and α2 GABAAR subunits that would predict such acceleration [198].

The synaptic connections from PVChCs onto the pyramidal cell AIS form vertical arrays of multiple synaptic boutons that are usually easy to distinguish and typically called cartridges. Developmental properties of inputs from PVChCs onto the AIS can be studied using immunocytochemistry to detect biochemical markers that are concentrated at the cartridges in the AIS. In monkey PFC, the density of chandelier neuron axon cartridges immunoreactive for either PV or GAT1 changes markedly during postnatal development [199]. Although the precise time course differs for the two markers, the density of labeled cartridges is low in the newborn, increases to reach a peak prior to the onset of puberty, and then declines markedly to adult levels. Because cartridges are readily visualized with the Golgi technique over this same time period [200], the changes in PV- and GAT1-immunoreactive cartridges may reflect developmental shifts in the concentration of these proteins, rather than in the number of axon terminals, but this remains to be experimentally assessed.

Substantial developmental changes also occur postsynaptically at the AIS. In the adult cortex, the majority of α2-GABAARs are found in pyramidal cell AIS [201]. The detectability of GABAA α2 subunits in AIS is very high in the early postnatal period and then steadily declines through adolescence into adulthood [199]. Immunoreactivity for ankyrin-G, βIV spectrin, and gephyrin (a scaffolding protein that regulates the clustering of GABAARs containing α2 subunits at AIS) [202204] also exhibit substantial changes during postnatal development [205]. The densities of ankyrin-G and βIV spectrin immunoreactive AISs are greatest at birth and then sharply decline to reach relatively stable values by one year of age. In contrast, the relative density of gephyrin-immunoreactive AIS did not appear to change through the two postnatal years but then sharply decline through adolescence and into adulthood.

The high density of AIS with detectable levels of ankyrin-G immunoreactivity in the first three postnatal months may reflect the recruitment to this location of a portion of the large number of GABA synapses that are formed in the monkey DLPFC during this developmental epoch [206]. Binding to ankyrin-G is also essential for the localization of many other membrane proteins to the AIS [207], including the voltage-gated Na+ channels that are required for action potential generation [208]. Thus, the high levels of ankyrin-G immunoreactivity may also indicate an increased capacity of pyramidal neurons for repetitive firing that parallels their increase in excitatory inputs during early postnatal development [206, 209]. The parallel relative densities of ankyrin-G-IR and βIV spectrin-SD-IR AIS likely reflect that ankyrin-G is required for the recruitment of βIV spectrin to AIS [210]. Although βIV spectrin is not essential for the formation of the AIS, it does appear necessary for maintenance of membrane structure and molecular organization [211], and thus the stability [210], of the AIS. Given the general role of spectrins in maintaining membrane integrity and elasticity [207], high levels of βIV spectrin during early postnatal development might insure the stability of AIS structure while PFC thickness is increasing [212].

Interestingly, in human PFC the levels of GAD67 mRNA increase progressively during prenatal and postnatal development through childhood until around the peripubertal period, followed by a plateau or mild decline during aging [213]. A similar pattern was reported for GAD67 mRNA expression during mouse [213] and monkey [214] cortical development, suggesting a highly conserved developmental trajectory of GAD67 expression across mammals. Studying protein expression by immunoblotting, a recent study found that GAD67 protein levels did not change across the lifespan in human visual cortex [215]. In contrast, GAD65 showed a progressive 60% increase until teenage years and young adulthood, followed by slight decline in older adults [215]. Two other presynaptic proteins involved in GABA transmission, the cannabinoid receptor 1 and vGAT, showed higher levels in infants and young children, which declined to adult-like levels in preteenage years [215]. The levels of PV mRNA increase markedly in postnatal human PFC, from very low perinatal levels until adult-like levels are reached by 2–5 years of age [216], an early developmental trajectory which is similar to that reported for PV mRNA and protein in rodent neocortex [217, 218].

Interestingly, a comparative analysis using immunolocalization of the chloride transporters NKCC1 and KCC2 revealed a very similar developmental trajectory in rat and human cortex [219]. NKCC1 levels peaking during perinatal development and decaying rapidly thereafter reach adult-like levels during childhood; conversely, KCC2 is undetectable perinatally and increases until reaching adult levels during childhood [219]. Since the NKCC1/KCC2 activity ratio determines whether GABAAR-mediated IPSCs depolarize or hyperpolarize the postsynaptic membrane, these data suggest that the very early developmental switch from excitatory to inhibitory effects at most GABA synapses [220] is highly conserved between rodent and human neocortex.

Analysis of GABAAR subunit proteins during postnatal development in human visual cortex showed that α1 GABAAR subunit levels increase from <1 years until reaching adult levels at 13.5 years of age, whereas α2 GABAAR subunits decreased significantly with age to reach adult levels by ~10 years and α3 GABAAR subunit levels do not change significantly with age [215]. Consequently, the α1/α2 subunit protein ratio increased markedly with development attaining adult-like ratios at 4.5 years of age [215]. Remarkably, very similar developmental trajectories were found for the levels of GABAAR subunit mRNAs in postmortem samples of human PFC [221]. For example, α1 GABAAR subunit mRNA levels are very low perinatally and increase markedly until toddler ages, thereafter remaining consistently high through to adulthood [221]. In contrast, α2 subunit mRNA increased during the first postnatal months, decreasing subsequently until reaching mature levels at teenage years or young adulthood [221]. The mRNAs for α4 and α5 GABAA subunits in human PFC showed a developmental pattern similar to that of α2 mRNA, whereas α3 subunit mRNA did not change significantly with age [221]. Postnatal expression of mRNA for γ and β GABAAR subunits similarly shows significant age-dependent changes, with β1 subunits showing a very early developmental decrease between neonate and infant ages, remaining constant thereafter, and β2 increasing somewhat later, between toddler and teenage years [222]. On the other hand, γ1 and γ3 subunit mRNA levels decrease with age during childhood and teenage years, whereas γ2 subunit mRNA levels decrease over the same period [222].

The developmental trajectories reviewed above suggest that similar processes underlie developmental changes in GABAAR-mediated synapses across various areas of human and rodent cortex, although further studies are necessary to properly compare developmental trajectories across species. A major difference between species is that the maturation of GABA-related markers in humans involves progressive change over one to two decades, whereas in rodents GABA synapse maturation appears to be complete within 3-4 postnatal weeks. Such difference suggests that the absolute time window during which activity and experience may influence GABA synapse development is markedly expanded in primate versus rodent brains. The prolonged period that may be necessary for the normal developmental tuning of the more complex circuitry of the primate cortex probably also prolongs the time window during which environmental factors can produce subtle developmental alterations that may contribute to the pathophysiology of schizophrenia.

6. Evidence Suggesting Alterations of GABAAR-Mediated Synaptic Transmission in the Cortex of Schizophrenia Patients

The hypothesis that a deficit in GABAAR-mediated transmission underlies cortical circuit dysfunction in schizophrenia is supported by convergent lines of evidence from post-mortem studies of the brain of subjects with schizophrenia [6]. Furthermore, such hypothesis is strengthened by the fact that one of the most reliably replicated findings in schizophrenia research is the decrease in GAD67 mRNA (for review, see [223]). Interestingly, equivalent measurements of GAD65 levels thus far failed to reveal alterations, suggesting that the role of GAD65 in GABA-mediated transmission maybe intact in schizophrenia.

A remarkable recent study found that in schizophrenia several GABA-related transcripts, including those for GAD67, PV, GAT1, somatostatin, and the GABAAR subunits α1 and δ, show decreased levels in dorsolateral PFC as well as in the anterior cingulate, primary motor, and primary visual cortices [224]. Such conserved regional pattern of GABA alterations suggests that dysfunctional GABA neurotransmission contributes to multiple clinical features of schizophrenia including perceptual and motor deficits that could contribute to impaired cognitive function [11]. The disruption of PV expression across cortical areas confirms the previous findings and, moreover, suggests that alterations of PV-positive cells are central to the schizophrenia disease process, although the consequences of such decrease in PV are not completely understood. PV is a Ca2+ buffer that is present in nerve terminals of PV-positive neurons (Figure 1). Due to its slow kinetics of Ca2+ binding, PV is unable to bind intracellular Ca2+ before Ca2+ influx activates the Ca2+ sensor that triggers GABA release, because in PV-positive terminals Ca2+ influx is tightly coupled with GABA release [110, 225]. Interestingly, GABA release by single stimuli does not differ between PV-deficient and wild-type mice, but PV deficiency facilitates repetitive GABA release [226228]. In synapses from PV-deficient mice, the amplitude of intracellular Ca2+ transients in nerve terminals is not affected, but their decay is slowed, indicating that PV normally accelerates such decay [227, 228]. Therefore, one possibility is that the decrease of PV in schizophrenia, instead of contributing to deficits, is a compensatory response to enhance GABA release in the face of decreased GABA synthesis. Alternatively, reduced PV levels may produce synaptic dysfunction via loss of some asynchronous release normally produced when Ca2+unbinds from PV, well after the presynaptic action potential ended [145]. A pathological loss of asynchronous GABA release by decreased PV levels, however, requires the existence of asynchronous release when PV is intact, a feature that is not observed in cortical PV-positive cells [104, 110], although it is found in PV-positive cerebellar interneurons [227].

Whereas schizophrenia may be associated with an increased density of α2-GABAARs at the AIS synapses from PVChCs [6], one study failed to detect significant changes in total tissue levels of α2-GABAAR mRNA [221]. One possibility is that changes in α2-GABAARs are synapse- or layer-specific and perhaps found exclusively at AIS synapses in superficial cortical layers, as initially reported [229]. Consistent with this interpretation, laminar analysis of mRNA levels for GABAAR subunits in the cortex of subjects with schizophrenia revealed significantly increased levels of mRNA for α2 GABAAR subunits exclusively in layer 2 [230]. Moreover, the same study revealed lower levels of α1 GABAAR subunit mRNA in layers 3 and 4 [230], which is consistent with a decrease in total tissue levels of α1 GABAAR subunit mRNA observed using quantitative PCR [224]. Given that α1 subunit-containing GABAARs constitute about 60% of the total GABAARs in adult brain [231], it is possible that α1 subunit mRNA is significantly more abundant than that for α2 subunits, thus increasing the chance of detecting changes of total tissue α1 mRNA levels in schizophrenia. Importantly, a decrease in α1 subunits in schizophrenia is consistent with weaker synaptic transmission from PVBCs, since α1 subunit-containing GABAARs are predominant at synapses from mature PVBCs [33, 41, 101, 102].

In addition to GABAAR levels, the strength of the postsynaptic response to GABA depends on the driving force for the GABAAR current which is determined by its reversal potential EGABAA. As EGABAA depends on chloride extrusion by KCC2 and chloride uptake by NKCC1 [43], a recent study examined mRNA expression for both chloride transporters in the cortex of subjects with schizophrenia [232]. Interestingly, KCC2 and NKCC1 transcript levels were not altered in subjects with schizophrenia; however, transcripts for two kinases (OXSR1 and WNK3) that strongly regulate KCC2 and NKCC1 activity in opposite directions, are overexpressed in schizophrenia [232]. If increased levels of OXSR1 and WNK3 mRNA actually represent increased kinase activity, then the chloride gradient across the postsynaptic membrane may be decreased, resulting in an EGABAA significantly more depolarized than normal [232]. Since normally EGABAA varies with cell type and subcellular compartment, understanding the consequences of alterations in chloride transport requires a detailed quantitative analysis of protein localization and activity, a challenging task in this case, given that postmortem interval effects alter the integrity of some of these proteins [232].

Direct demonstration that GABA-mediated synaptic inhibition is decreased in the cortex of subjects with schizophrenia is challenging. Interestingly, magnetic resonance spectroscopy (MRS) was recently applied to noninvasively measured GABA concentration in human neocortex and determined whether a decrease of GABA is observed in schizophrenia. MRS does not distinguish extracellular GABA from transmitter stored in particular cellular compartments or cell types and also lacks adequate temporal resolution but nevertheless reveals activity-dependent changes in GABA levels. For example, acute psychological stress which elevates subjective anxiety produces a short-term decrease in GABA concentration in human dorsolateral PFC that can be detected with MRS [233]. Combining MRS and EEG in the same subjects, the relations between brain GABA content and oscillatory neural activity in schizophrenia may be explored. Interestingly, in normal human subjects, GABA concentration measured in visual cortex with MRS was positively correlated with the strength of gamma oscillations induced by visual stimulation [234]. Moreover, interindividual variation in GABA concentration determined by MRS in visual cortex was correlated with variability of performance in a visual stimulus orientation discrimination task that induces gamma oscillations [235].

Measurements of tissue GABA concentration with MRS may help in clarifying the relations between GAD67 levels, gamma oscillations, and cognitive performance in schizophrenia. One such study did not detect differences in GABA concentration in the anterior cingulate cortex of schizophrenia versus control subjects, whereas GABA concentration was apparently decreased by antipsychotic medications [236]. Another MRS study reported reduced GABA concentration in basal ganglia but not frontal cortex of schizophrenia patients [237]. In patients with relatively low antipsychotic exposure, MRS revealed a significant reduction of GABA concentration in visual cortex that did not covary with medication dosage but was correlated with behavioral abnormalities in a visual surround-suppression task thought to depend on GABA-mediated inhibition [238]. Moreover, a longitudinal study of early-stage first-episode schizophrenia patients showed that 6 months of treatment with atypical antipsychotics did not change GABA concentrations measured with MRS in frontal and parietal lobe cortices nor in basal ganglia [239]. In contrast, MRS revealed elevated GABA concentration in anterior cingulate and parietal cortex of subjects with chronically treated schizophrenia compared to control subjects [240]. The MRS findings suggesting that antipsychotics may change brain GABA concentration highlight the importance of addressing the effects of confounding factors such as medications [241]. Significantly, both postmortem studies in humans and experimental studies in animals have failed to show an effect of antipsychotic medications on GAD67 mRNA levels [224, 242, 243]. The data from MRS studies therefore underscore the importance of combining neurochemical, electrophysiological, and behavioral assessment, given the large interindividual variability in bulk GABA concentration, gamma activity levels, and behavioral performance. Instead of or in addition to medication effects, the large variability in cortical GABA content measured with MRS in human cortex may be explained by the effects of genetic variants in the GAD1 gene that may differentially confer risk of schizophrenia [244].

7. Conclusions

The findings reviewed here suggest that alterations of GABA transmission produce cognitive deficits in schizophrenia by altering the circuit mechanisms of gamma oscillations. These observations suggest a molecular and cellular basis for the development of new therapeutic interventions [245]. Importantly, the proposal that GABA alterations are linked to altered gamma oscillations and cognition is supported, at least in part, by animal model studies showing that producing a functional loss of GABA-mediated inhibition diminishes gamma oscillations [246] and impairs cognitive function [247, 248]. Whereas work in animal models is essential, the difficulty of capturing in animals the complexity of behavioral alterations in a uniquely human disorder may explain the relative lack of success in developing drugs to treat schizophrenia compared with other disease areas [4, 5, 245]. Interpretation of studies in human subjects based on comparisons between healthy controls and patients is complicated as well, given that schizophrenia versus control differences may actually reflect pathogenesis but also could represent compensatory changes or effects of confounding factors [4, 241]. For example, the effects of producing a transient deficit in GABAAR-mediated signaling were tested recently in human subjects [249] using iomazenil, a compound that binds to the benzodiazepine site of GABAARs and negatively modulates the effects of GABA (i.e., an inverse agonist). Consistent with dysfunctional GABAAR signaling in schizophrenia, iomazenil produced perceptual deficits and psychotic symptoms in schizophrenia patients at doses that did not affect healthy control subjects [249]. However, the schizophrenia patients in such study chronically received antipsychotics and anxiolytics, raising the question of whether an interaction between acute iomazenil and chronic medications influenced such findings.

Preliminary tests of the idea that enhancing GABAAR signaling improves behavioral and electrophysiological measures in subjects with schizophrenia were conducted in two recent studies evaluating the effects of MK-0777, an α2/α3 GABAAR-preferring positive allosteric modulator [47]. In one study, randomized administration of MK-0777 or placebo in double-blind fashion improved performance of schizophrenia patients in a cognitive control task, simultaneously increasing gamma oscillation power in frontal cortex [250]. In contrast, the second study did not find significant effects of MK-0777 compared with placebo in the performance of patients in a battery of tests designed to assess cognitive function in schizophrenia [251]. The inconsistent beneficial effects of MK-0777 administration might be explained by the fact that MK-0777 is a partial agonist at α2/α3 subunit-containing GABAARs with only about 10–20% potency compared to a full agonist [48]. Thus, one possibility is that more potent α2/α3 benzodiazepine site agonists need to be employed. Such drugs should also be more selective because, compared with placebo, MK-0777 had a tendency to produce sedation and somnolence [250, 251], which could mask improvements in cognitive performance. Importantly, the α2/α3 GABAAR modulator MK-0777 was selected based on the compelling rationale that inputs from PVChCs onto the AIS show important alterations in schizophrenia [83] and that, depending on cortical layer, such inputs involve α2-GABAARs or α3-GABAARs [101, 201, 252]. However, whether or not PVChCs play a role in production of gamma band synchrony remains unclear [82], and so it is possible that PVChC alterations in schizophrenia produce cognitive deficits unrelated to dysfunctional gamma band synchrony. Therefore, further information from both basic and clinical research studies is necessary to further assess the effectiveness of α2/α3 GABAAR modulators for treatment of gamma synchrony-related cognitive deficits in schizophrenia. Indeed, basic research studies continue to provide insight into the role of specific subtypes of GABA neurons on inhibition-mediated cortical network oscillations [127], and molecular pharmacology studies are identifying novel compounds acting at different sites within the GABAAR receptor complex [44, 47, 253].

Importantly, a potential role of GABA-mediated neural synchrony in cortical circuits is to enable spike-timing-dependent plasticity, indirectly modifying the strength and stability of excitatory synaptic connections [254]. Whether spike-timing-dependent plasticity at glutamate synapses is impaired in schizophrenia is not yet clear [12], but it is possible that the decrease of dendritic spine density in pyramidal neurons in schizophrenia is due to glutamate synapse loss produced by altered plasticity mechanisms [241]. If neural synchrony-dependent glutamate synaptic plasticity is dysfunctional in schizophrenia, then cognitive enhancement behavioral therapies that involve learning paradigms may help in preventing or reversing the consequences of altered circuitry on the induction of synaptic plasticity. Interestingly, cognitive enhancement behavioral therapy was recently shown to improve cognition and prevent gray matter loss in schizophrenia [255]. Potentially, combining cognitive therapies with pharmacological treatment that boosts otherwise weakened neural synchrony may constitute an effective treatment intervention in schizophrenia, as for other psychiatric disorders [256].

Acknowledgment

The published work cited in this review article and conducted by the authors was funded by NARSAD and NIH Grants MH051234, MH084053, MH071533, and MH085108.

References

1. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? The American Journal of Psychiatry. 1996;153(3):321–330. [PubMed]
2. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine. 2005;353(12):1209–1223. [PubMed]
3. Carpenter WT, Buchanan RW. Lessons to take home from CATIE. Psychiatric Services. 2008;59(5):523–525. [PubMed]
4. Agid Y, Buzsáki G, Diamond DM, et al. How can drug discovery for psychiatric disorders be improved? Nature Reviews Drug Discovery. 2007;6(3):189–201. [PubMed]
5. Abbott A. Schizophrenia: the drug deadlock. Nature. 2010;468:158–159. [PubMed]
6. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nature Reviews Neuroscience. 2005;6(4):312–324. [PubMed]
7. Bartos M, Vida I, Jonas P. Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nature Reviews Neuroscience. 2007;8(1):45–56. [PubMed]
8. Whittington MA, Cunningham MO, LeBeau FE, Racca C, Traub RD. Multiple origins of the cortical gamma rhythm. Developmental Neurobiology. 2011;71:92–106. [PubMed]
9. Fries P. Neuronal gamma-band synchronization as a fundamental process in cortical computation. Annual Review of Neuroscience. 2009;32:209–224. [PubMed]
10. Lesh TA, Niendam TA, Minzenberg MJ, Carter CS. Cognitive control deficits in schizophrenia: mechanisms and meaning. Neuropsychopharmacology. 2011;36:316–338. [PMC free article] [PubMed]
11. Haenschel C, Linden D. Exploring intermediate phenotypes with EEG: working memory dysfunction in schizophrenia. Behavioural Brain Research. 2011;216:481–495. [PubMed]
12. Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nature Reviews Neuroscience. 2010;11(2):100–113. [PubMed]
13. Spencer KM, Nestor PG, Niznikiewicz MA, Salisbury DF, Shenton ME, McCarley RW. Abnormal neural synchrony in schizophrenia. The Journal of Neuroscience. 2003;23(19):7407–7411. [PMC free article] [PubMed]
14. Baddeley A. Working memory. Current Biology. 2010;20(4):R136–R140. [PubMed]
15. Howard MW, Rizzuto DS, Caplan JB, et al. Gamma oscillations correlate with working memory load in humans. Cerebral Cortex. 2003;13(12):1369–1374. [PubMed]
16. Basar-Eroglu C, Brand A, Hildebrandt H, Kedzior KK, Mathes B, Schmiedt C. Working memory related gamma oscillations in schizophrenia patients. International Journal of Psychophysiology. 2007;64(1):39–45. [PubMed]
17. Barr MS, Farzan F, Tran LC, Chen R, Fitzgerald PB, Daskalakis ZJ. Evidence for excessive frontal evoked gamma oscillatory activity in schizophrenia during working memory. Schizophrenia Research. 2010;121:146–152. [PubMed]
18. Haenschel C, Bittner RA, Waltz J, et al. Cortical oscillatory activity is critical for working memory as revealed by deficits in early-onset schizophrenia. The Journal of Neuroscience. 2009;29(30):9481–9489. [PubMed]
19. Meyer-Lindenberg A. From maps to mechanisms through neuroimaging of schizophrenia. Nature. 2010;468:194–202. [PubMed]
20. Miller EK, Cohen JD. An integrative theory of prefrontal cortex function. Annual Review of Neuroscience. 2001;24:167–202. [PubMed]
21. Cho RY, Konecky RO, Carter CS. Impairments in frontal cortical γ synchrony and cognitive control in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(52):19878–19883. [PMC free article] [PubMed]
22. Minzenberg MJ, Firl AJ, Yoon JH, Gomes GC, Reinking C, Carter CS. Gamma oscillatory power is impaired during cognitive control independent of medication status in first-episode schizophrenia. Neuropsychopharmacology. 2010;35:2590–2599. [PMC free article] [PubMed]
23. Spencer KM, Salisbury DF, Shenton ME, McCarley RW. Gamma-band auditory steady-state responses are impaired in first episode psychosis. Biological Psychiatry. 2008;64(5):369–375. [PMC free article] [PubMed]
24. Spencer KM, Niznikiewicz MA, Nestor PG, Shenton ME, McCarley RW. Left auditory cortex gamma synchronization and auditory hallucination symptoms in schizophrenia. BMC Neuroscience. 2009;10:p. 85. [PMC free article] [PubMed]
25. Soghomonian JJ, Martin DL. Two isoforms of glutamate decarboxylase: why? Trends in Pharmacological Sciences. 1998;19:500–505. [PubMed]
26. Buhl EH, Halasy K, Somogyi P. Diverse sources of hippocampal unitary inhibitory postsynaptic potentials and the number of synaptic release sites. Nature. 1994;368(6474):823–828. [PubMed]
27. Buhl EH, Cobb SR, Halasy K, Somogyi P. Properties of unitary IPSPs evoked by anatomically identified basket cells in the rat hippocampus. The European The Journal of Neuroscience. 1995;7(9):1989–2004. [PubMed]
28. Cobb SR, Buhl EH, Halasy K, Paulsen O, Somogyl P. Synchronization of neuronal activity in hippocampus by individual GABAergic interneurons. Nature. 1995;378(6552):75–78. [PubMed]
29. Ali AB, Bannister AP, Thomson AM. IPSPs elicited in CA1 pyramidal cells by putative basket cells in slices of adult rat hippocampus. The European The Journal of Neuroscience. 1999;11(5):1741–1753. [PubMed]
30. Pawelzik H, Bannister AP, Deuchars J, Ilia M, Thomson AM. Modulation of bistratified cell IPSPs and basket cell IPSPs by pentobarbitone sodium, diazepam and Zn2+: dual recordings in slices of adult rat hippocampus. The European The Journal of Neuroscience. 1999;11:3552–3564. [PubMed]
31. Thomson AM, Bannister AP, Hughes DI, Pawelzik H. Differential sensitivity to Zolpidem of IPSPs activated by morphologically identified CA1 interneurons in slices of rat hippocampus. The European The Journal of Neuroscience. 2000;12(2):425–436. [PubMed]
32. Bartos M, Vida I, Frotscher M, et al. Fast synaptic inhibition promotes synchronized gamma oscillations in hippocampal interneuron networks. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(20):13222–13227. [PMC free article] [PubMed]
33. Doischer D, Hosp JA, Yanagawa Y, et al. Postnatal differentiation of basket cells from slow to fast signaling devices. The Journal of Neuroscience. 2008;28(48):12956–12968. [PubMed]
34. Thomson AM, West DC, Hahn J, Deuchars J. Single axon IPSPs elicited in pyramidal cells by three classes of interneurones in slices of rat neocortex. Journal of Physiology. 1996;496(1):81–102. [PMC free article] [PubMed]
35. Tamás G, Buhl EH, Somogyi P. Fast IPSPs elicited via multiple synaptic release sites by different types of GABAergic neurone in the cat visual cortex. Journal of Physiology. 1997;500, part 3:715–738. [PMC free article] [PubMed]
36. Tamás G, Somogyi P, Buhl EH. Differentially interconnected networks of GABAergic interneurons in the visual cortex of the cat. The Journal of Neuroscience. 1998;18(11):4255–4270. [PubMed]
37. Thomson AM, Destexhe A. Dual intracellular recordings and computational models of slow inhibitory postsynaptic potentials in rat neocortical and hippocampal slices. Neuroscience. 1999;92(4):1193–1215. [PubMed]
38. Tamás G, Lörincz A, Simon A, Szabadics J. Identified sources and targets of slow inhibition in the neocortex. Science. 2003;299(5614):1902–1905. [PubMed]
39. González-Burgos G, Krimer LS, Povysheva NV, Barrionuevo G, Lewis DA. Functional properties of fast spiking interneurons and their synaptic connections with pyramidal cells in primate dorsolateral prefrontal cortex. Journal of Neurophysiology. 2005;93(2):942–953. [PubMed]
40. Szabadics J, Varga C, Molnár G, Oláh S, Barzó P, Tamás G. Excitatory effect of GABAergic axo-axonic cells in cortical microcircuits. Science. 2006;311(5758):233–235. [PubMed]
41. Szabadics J, Tamás G, Soltesz I. Different transmitter transients underlie presynaptic cell type specificity of GABAA, slow and GABAA, fast. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(37):14831–14836. [PMC free article] [PubMed]
42. Oláh S, Füle M, Komlósi G, et al. Regulation of cortical microcircuits by unitary GABA-mediated volume transmission. Nature. 2009;461(7268):1278–1281. [PMC free article] [PubMed]
43. Farrant M, Kaila K. The cellular, molecular and ionic basis of GABA receptor signalling. Progress in Brain Research. 2007;160:59–87. [PubMed]
44. Olsen RW, Sieghart W. GABA A receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology. 2009;56(1):141–148. [PMC free article] [PubMed]
45. Sigel E. Mapping of the benzodiazepine recognition site on GABA(A) receptors. Current Topics in Medicinal Chemistry. 2002;2(8):833–839. [PubMed]
46. Hanson SM, Czajkowski C. Structural mechanisms underlying benzodiazepine modulation of the GABA(A) receptor. The Journal of Neuroscience. 2008;28(13):3490–3499. [PMC free article] [PubMed]
47. Mohler H. The rise of a new GABA pharmacology. Neuropharmacology. 2010;60(7-8):1042–1049. [PubMed]
48. Atack JR, Wafford KA, Tye SJ, et al. TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluor ophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates. Journal of Pharmacology and Experimental Therapeutics. 2006;316:410–422. [PubMed]
49. Johnston D, Wu SM-S. Foundations of Cellular Neurophysiology. 1st edition. Cambridge, Mass, USA: MIT Press; 1995.
50. Gulledge AT, Stuart GJ. Excitatory actions of GABA in the cortex. Neuron. 2003;37(2):299–309. [PubMed]
51. Stuart G, Sakmann B. Amplification of EPSPs by axosomatic sodium channels in neocortical pyramidal neurons. Neuron. 1995;15(5):1065–1076. [PubMed]
52. González-Burgos G, Barrionuevo G. Voltage-gated sodium channels shape subthreshold EPSPs in layer 5 pyramidal neurons from rat prefrontal cortex. Journal of Neurophysiology. 2001;86(4):1671–1684. [PubMed]
53. Overstreet LS, Westbrook GL. Synapse density regulates independence at unitary inhibitory synapses. The Journal of Neuroscience. 2003;23(7):2618–2626. [PubMed]
54. Jensen K, Chiu CS, Sokolova I, Lester HA, Mody I. GABA transporter-1 (GAT1)-deficient mice: differential tonic activation of GABA versus GABA receptors in the hippocampus. Journal of Neurophysiology. 2003;90(4):2690–2701. [PubMed]
55. Bragina L, Marchionni I, Omrani A, et al. GAT-1 regulates both tonic and phasic GABA(A) receptor-mediated inhibition in the cerebral cortex. Journal of Neurochemistry. 2008;105(5):1781–1793. [PubMed]
56. Gonzalez-Burgos G, Rotaru DC, Zaitsev AV, Povysheva NV, Lewis DA. GABA transporter GAT1 prevents spillover at proximal and distal GABA synapses onto primate prefrontal cortex neurons. Journal of Neurophysiology. 2009;101(2):533–547. [PMC free article] [PubMed]
57. Minelli A, Brecha NC, Karschin C, DeBiasi S, Conti F. GAT-1, a high-affinity GABA plasma membrane transporter, is localized to neurons and astroglia in the cerebral cortex. The Journal of Neuroscience. 1995;15(11):7734–7746. [PubMed]
58. Conti F, Melone M, De Biasi S, Minelli A, Brecha NC, Ducati A. Neuronal and glial localization of GAT-1, a high-affinity γ- aminobutyric acid plasma membrane transporter, in human cerebral cortex: with a note on its distribution in monkey cortex. Journal of Comparative Neurology. 1998;396(1):51–63. [PubMed]
59. Ong WY, Yeo TT, Balcar VJ, Garey LJ. A light and electron microscopic study of GAT-1-positive cells in the cerebral cortex of man and monkey. Journal of Neurocytology. 1998;27(10):719–730. [PubMed]
60. Vitellaro-Zuccarello L, Calvaresi N, De Biasi S. Expression of GABA transporters, GAT-1 and GAT-3, in the cerebral cortex and thalamus of the rat during postnatal development. Cell and Tissue Research. 2003;313(3):245–257. [PubMed]
61. Mahendrasingam S, Wallam CA, Hackney CM. Two approaches to double post-embedding immunogold labeling of freeze-substituted tissue embedded in low temperature Lowicryl HM20 resin. Brain Research Protocols. 2003;11(2):134–141. [PubMed]
62. Conti F, Minelli A, Melone M. GABA transporters in the mammalian cerebral cortex: localization, development and pathological implications. Brain Research Reviews. 2004;45(3):196–212. [PubMed]
63. Chen NH, Reith ME, Quick MW. Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6. Pflugers Archiv European Journal of Physiology. 2004;447(5):519–531. [PubMed]
64. Bicho A, Grewer C. Rapid substrate-induced charge movements of the GABA transporter GAT1. Biophysical Journal. 2005;89(1):211–231. [PMC free article] [PubMed]
65. Borden LA. GABA transporter heterogeneity: pharmacology and cellular localization. Neurochemistry International. 1996;29:335–356. [PubMed]
66. Keros S, Hablitz JJ. Subtype-specific GABA transporter antagonists synergistically modulate phasic and tonic GABAA conductances in rat neocortex. Journal of Neurophysiology. 2005;94:2073–2085. [PubMed]
67. Whittington MA, Traub RD, Kopell N, Ermentrout B, Buhl EH. Inhibition-based rhythms: experimental and mathematical observations on network dynamics. International Journal of Psychophysiology. 2000;38(3):315–336. [PubMed]
68. Gonzalez-Burgos G, Lewis DA. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophrenia Bulletin. 2008;34(5):944–961. [PMC free article] [PubMed]
69. Ermentrout GB, Galán RF, Urban NN. Reliability, synchrony and noise. Trends in Neurosciences. 2008;31(8):428–434. [PMC free article] [PubMed]
70. Buzsáki G, Draguhn A. Neuronal olscillations in cortical networks. Science. 2004;304(5679):1926–1929. [PubMed]
71. Wang XJ. Neurophysiological and computational principles of cortical rhythms in cognition. Physiological Reviews. 2010;90(3):1195–1268. [PMC free article] [PubMed]
72. Ascoli GA, Alonso-Nanclares L, Anderson SA, et al. Petilla terminology: nomenclature of features of GABAergic interneurons of the cerebral cortex. Nature Reviews Neuroscience. 2008;9:557–568. [PMC free article] [PubMed]
73. Kopell N, Kramer MA, Malerba P, Whittington MA. Are different rhythms good for different functions? Frontiers in Human Neuroscience. 2010;4:p. 187. [PMC free article] [PubMed]
74. Stuart G, Spruston N, Sakmann B, Häusser M. Action potential initiation and backpropagation in neurons of the mammalian CNS. Trends in Neurosciences. 1997;20(3):125–131. [PubMed]
75. Miles R, Tóth K, Gulyás AI, Hájos N, Freund TF. Differences between somatic and dendritic inhibition in the hippocampus. Neuron. 1996;16(4):815–823. [PubMed]
76. Williams SR, Stuart GJ. Voltage- and site-dependent control of the somatic impact of dendritic IPSPs. The Journal of Neuroscience. 2003;23(19):7358–7367. [PubMed]
77. Báldi R, Varga C, Tamás G. Differential distribution of KCC2 along the axo-somato-dendritic axis of hippocampal principal cells. The European The Journal of Neuroscience. 2010;32(8):1319–1325. [PubMed]
78. Woodruff A, Xu Q, Anderson SA, Yuste R. Depolarizing effect of neocortical chandelier neurons. Frontiers in Neural Circuits . 2009;3, article 13 [PMC free article] [PubMed]
79. Khirug S, Yamada J, Afzalov R, Voipio J, Kaila K. GABAergic depolarization of the axon initial segment in cortical principal neurons is caused by the Na-K-2Cl cotransporter NKCC1. The Journal of Neuroscience. 2008;28(18):4635–4639. [PubMed]
80. Vida I, Bartos M, Jonas P. Shunting inhibition improves robustness of gamma oscillations in hippocampal interneuron networks by homogenizing firing rates. Neuron. 2006;49(1):107–117. [PubMed]
81. Glickfeld LL, Roberts JD, Somogyi P, Scanziani M. Interneurons hyperpolarize pyramidal cells along their entire somatodendritic axis. Nature Neuroscience. 2009;12(1):21–23. [PMC free article] [PubMed]
82. Woodruff AR, Anderson SA, Yuste R. The enigmatic function of chandelier cells. Frontiers in Neuroscience. 2010;4:p. 201. [PMC free article] [PubMed]
83. Lewis DA. The chandelier neuron in schizophrenia. Developmental Neurobiology. 2011;71:118–127. [PMC free article] [PubMed]
84. Földy C, Lee SH, Morgan RJ, Soltesz I. Regulation of fast-spiking basket cell synapses by the chloride channel ClC-2. Nature Neuroscience. 2010;13(9):1047–1049. [PMC free article] [PubMed]
85. Fish KN, Sweet RA, Lewis DA. Differential distribution of proteins regulating GABA synthesis and reuptake in axon boutons of subpopulations of cortical interneurons. Cerebral Cortex. In press. [PMC free article] [PubMed]
86. Fish KN, Sweet RA, Deo AJ, Lewis DA. An automated segmentation methodology for quantifying immunoreactive puncta number and fluorescence intensity in tissue sections. Brain Research. 2008;1240:62–72. [PMC free article] [PubMed]
87. Eggan SM, Melchitzky DS, Sesack SR, Fish KN, Lewis DA. Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex. Neuroscience. 2010;169:1651–1661. [PMC free article] [PubMed]
88. Asada H, Kawamura Y, Maruyama K, et al. Cleft palate and decreased brain γ-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(12):6496–6499. [PMC free article] [PubMed]
89. Ji F, Obata K. Development of the GABA system in organotypic culture of hippocampal and cerebellar slices from a 67-kDa isoform of glutamic acid decarboxylase (GAD67)-deficient mice. Neuroscience Research. 1999;33(3):233–237. [PubMed]
90. Asada H, Kawamura Y, Maruyama K, et al. Mice lacking the 65 kDa isoform of glutamic acid decarboxylase (GAD65) maintain normal levels of GAD67 and GABA in their brains but are susceptible to seizures. Biochemical and Biophysical Research Communications. 1996;229(3):891–895. [PubMed]
91. Kash SF, Johnson RS, Tecott LH, et al. Epilepsy in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(25):14060–14065. [PMC free article] [PubMed]
92. Kash SF, Tecott LH, Hodge C, Baekkeskov S. Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(4):1698–1703. [PMC free article] [PubMed]
93. Sangha S, Narayanan RT, Bergado-Acosta JR, Stork O, Seidenbecher T, Pape HC. Deficiency of the 65 kDa isoform of glutamic acid decarboxylase impairs extinction of cued but not contextual fear memory. The Journal of Neuroscience. 2009;29(50):15713–15720. [PubMed]
94. Tian N, Petersen C, Kash S, Baekkeskov S, Copenhagen D, Nicoll R. The role of the synthetic enzyme GAD65 in the control of neuronal γ-aminobutyric acid release. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(22):12911–12916. [PMC free article] [PubMed]
95. Choi SY, Morales B, Lee HK, Kirkwood A. Absence of long-term depression in the visual cortex of glutamic acid decarboxylase-65 knock-out mice. The Journal of Neuroscience. 2002;22(13):5271–5276. [PubMed]
96. Obata K, Hirono M, Kume N, Kawaguchi Y, Itohara S, Yanagawa Y. GABA and synaptic inhibition of mouse cerebellum lacking glutamate decarboxylase 67. Biochemical and Biophysical Research Communications. 2008;370(3):429–433. [PubMed]
97. Chattopadhyaya B, Di CG, Wu CZ, et al. GAD67-mediated GABA synthesis and signaling regulate inhibitory synaptic innervation in the visual cortex. Neuron. 2007;54(6):889–903. [PMC free article] [PubMed]
98. Sheikh SN, Martin SB, Martin DL. Regional distribution and relative amounts of glutamate decarboxylase isoforms in rat and mouse brain. Neurochemistry International. 1999;35(1):73–80. [PubMed]
99. Capogna M, Pearce RA. GABA(A, slow): causes and consequences. Trends in Neurosciences. 2010;34(2):101–112 . [PubMed]
100. Lavole AM, Tingey JJ, Harrison NL, Pritchett DB, Twyman RE. Activation and deactivation rates of recombinant GABA(A) receptor channels are dependent on α-subunit isoform. Biophysical Journal. 1997;73(5):2518–2526. [PMC free article] [PubMed]
101. Nusser Z, Sieghart W, Benke D, Fritschy JM, Somogyi P. Differential synaptic localization of two major gamma-aminobutyric acid type A receptor alpha subunits on hippocampal pyramidal cells. Proceedings of the National Academy of Sciences of the United States of America. 1996;93:11939–11944. [PMC free article] [PubMed]
102. Klausberger T, Roberts JD, Somogyi P. Cell type- and input-specific differences in the number and subtypes of synaptic GABA(A) receptors in the hippocampus. The Journal of Neuroscience. 2002;22(7):2513–2521. [PubMed]
103. Freund TF, Katona I. Perisomatic inhibition. Neuron. 2007;56(1):33–42. [PubMed]
104. Hefft S, Jonas P. Asynchronous GABA release generates long-lasting inhibition at a hippocampal interneuron-principal neuron synapse. Nature Neuroscience. 2005;8(10):1319–1328. [PubMed]
105. Galarreta M, Erdélyi F, Szabó G, Hestrin S. Cannabinoid sensitivity and synaptic properties of 2 GABAergic networks in the neocortex. Cerebral Cortex. 2008;18(10):2296–2305. [PMC free article] [PubMed]
106. Glickfeld LL, Atallah BV, Scanziani M. Complementary modulation of somatic inhibition by opioids and cannabinoids. The Journal of Neuroscience. 2008;28(8):1824–1832. [PMC free article] [PubMed]
107. Szabo GG, Holderith N, Gulyas AI, Freund TF, Hajos N. Distinct synaptic properties of perisomatic inhibitory cell types and their different modulation by cholinergic receptor activation in the CA3 region of the mouse hippocampus. The European The Journal of Neuroscience. 2010;31:2234–2246. [PMC free article] [PubMed]
108. Jones MV, Westbrook GL. Shaping of IPSCs by endogenous calcineurin activity. The Journal of Neuroscience. 1997;17(20):7626–7633. [PubMed]
109. Nusser Z, Sieghart W, Mody I. Differential regulation of synaptic GABA(A) receptors by cAMP-dependent protein kinase in mouse cerebellar and olfactory bulb neurones. Journal of Physiology. 1999;521, part 2:421–435. [PMC free article] [PubMed]
110. Bucurenciu I, Kulik A, Schwaller B, Frotscher M, Jonas P. Nanodomain coupling between Ca2+ channels and Ca2+ sensors promotes fast and efficient transmitter release at a cortical GABAergic synapse. Neuron. 2008;57(4):536–545. [PubMed]
111. Daw MI, Tricoire L, Erdelyi F, Szabo G, McBain CJ. Asynchronous transmitter release from cholecystokinin-containing inhibitory interneurons is widespread and target-cell independent. The Journal of Neuroscience. 2009;29(36):11112–11122. [PMC free article] [PubMed]
112. Karson MA, Tang AH, Milner TA, Alger BE. Synaptic cross talk between perisomatic-targeting interneuron classes expressing cholecystokinin and parvalbumin in hippocampus. The Journal of Neuroscience. 2009;29(13):4140–4154. [PMC free article] [PubMed]
113. Ali AB, Todorova M. Asynchronous release of GABA via tonic cannabinoid receptor activation at identified interneuron synapses in rat CA1. The European The Journal of Neuroscience. 2010;31(7):1196–1207. [PubMed]
114. Daw MI, Pelkey KA, Chittajallu R, McBain CJ. Presynaptic kainate receptor activation preserves asynchronous GABA release despite the reduction in synchronous release from hippocampal cholecystokinin interneurons. The Journal of Neuroscience. 2010;30(33):11202–11209. [PMC free article] [PubMed]
115. Jonas P, Hefft S. GABA release at terminals of CCK-interneurons: synchrony, asynchrony and modulation by cannabinoid receptors (Commentary on Ali & Todorova) The European The Journal of Neuroscience. 2010;31(7):1194–1195. [PubMed]
116. Bragin A, Jando G, Nadasdy Z, Hetke J, Wise K, Buzsaki G. Gamma (40–100 Hz) oscillation in the hippocampus of the behaving rat. The Journal of Neuroscience. 1995;15(1 I):47–60. [PubMed]
117. Penttonen M, Kamondi A, Acsady L, Buzsáki G. Gamma frequency oscillation in the hippocampus of the rat: intracellular analysis in vivo. The European The Journal of Neuroscience. 1998;10(2):718–728. [PubMed]
118. Tukker JJ, Fuentealba P, Hartwich K, Somogyi P, Klausberger T. Cell type-specific tuning of hippocampal interneuron firing during gamma oscillations in vivo. The Journal of Neuroscience. 2007;27(31):8184–8189. [PubMed]
119. Hajos N, Palhalmi J, Mann EO, Nemeth B, Paulsen O, Freund TF. Spike timing of distinct types of GABAergic interneuron during hippocampal gamma oscillations in vitro. The Journal of Neuroscience. 2004;24:9127–9137. [PubMed]
120. Gloveli T, Dugladze T, Saha S, et al. Differential involvement of oriens/pyramidale interneurones in hippocampal network oscillations in vitro. Journal of Physiology. 2005;562(1):131–147. [PMC free article] [PubMed]
121. Mann EO, Suckling JM, Hajos N, Greenfield SA, Paulsen O. Perisomatic feedback inhibition underlies cholinergically induced fast network oscillations in the rat hippocampus in vitro. Neuron. 2005;45(1):105–117. [PubMed]
122. Oren I, Mann EO, Paulsen O, Hájos N. Synaptic currents in anatomically identified CA3 neurons during hippocampal gamma oscillations in vitro. The Journal of Neuroscience. 2006;26(39):9923–9934. [PubMed]
123. Oren I, Hájos N, Paulsen O. Identification of the current generator underlying cholinergically induced gamma frequency field potential oscillations in the hippocampal CA3 region. Journal of Physiology. 2010;588(5):785–797. [PMC free article] [PubMed]
124. Gulyas AI, Szabo GG, Ulbert I, et al. Parvalbumin-containing fast-spiking basket cells generate the field potential oscillations induced by cholinergic receptor activation in the hippocampus. The Journal of Neuroscience. 2010;30:15134–15145. [PMC free article] [PubMed]
125. Klausberger T, Magill PJ, Márton LF, et al. Brain-state- and cell-type-specific firing of hippocampal interneurons in vivo. Nature. 2003;421(6925):844–848. [PubMed]
126. Klausberger T, Marton LF, O’Neill J, et al. Complementary roles of cholecystokinin- and parvalbumin-expressing GABAergic neurons in hippocampal network oscillations. The Journal of Neuroscience. 2005;25(42):9782–9793. [PubMed]
127. Klausberger T, Somogyi P. Neuronal diversity and temporal dynamics: the unity of hippocampal circuit operations. Science. 2008;321(5885):53–57. [PubMed]
128. Sohal VS, Zhang F, Yizhar O, Deisseroth K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature. 2009;459(7247):698–702. [PMC free article] [PubMed]
129. Gibson JR, Belerlein M, Connors BW. Two networks of electrically coupled inhibitory neurons in neocortex. Nature. 1999;402(6757):75–79. [PubMed]
130. Galarreta M, Hestrin S. Electrical and chemical synapses among parvalbumin fast-spiking GABAergic interneurons in adult mouse neocortex. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(19):12438–12443. [PMC free article] [PubMed]
131. van Vreeswijk C, Abbott LF, Bard Ermentrout G. When inhibition not excitation synchronizes neural firing. Journal of Computational Neuroscience. 1994;1(4):313–321. [PubMed]
132. Wang XJ, Buzsáki G. Gamma oscillation by synaptic inhibition in a hippocampal interneuronal network model. The Journal of Neuroscience. 1996;16(20):6402–6413. [PubMed]
133. Traub RD, Whittington MA, Colling SB, Buzsáki G, Jefferys JG. Analysis of gamma rhythms in the rat hippocampus in vitro and in vivo. Journal of Physiology. 1996;493(2):471–484. [PMC free article] [PubMed]
134. Whittington MA, Traub RD, Jefferys JG. Synchronized oscillation in interneuron networks driven by metabotropic glutamate receptor activation. Nature. 1995;373(6515):612–615. [PubMed]
135. Fisahn A, Contractor A, Traub RD, Buhl EH, Heinemann SF, McBain CJ. Distinct roles for the kainate receptor subunits GluR5 and GluR6 in kainate-induced hippocampal gamma oscillations. The Journal of Neuroscience. 2004;24(43):9658–9668. [PubMed]
136. Wulff P, Ponomarenko AA, Bartos M, et al. Hippocampal theta rhythm and its coupling with gamma oscillations require fast inhibition onto parvalbumin-positive interneurons. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(9):3561–3566. [PMC free article] [PubMed]
137. Lisman J, Buzsáki G. A neural coding scheme formed by the combined function of gamma and theta oscillations. Schizophrenia Bulletin. 2008;34(5):974–980. [PMC free article] [PubMed]
138. Hájos N, Paulsen O. Network mechanisms of gamma oscillations in the CA3 region of the hippocampus. Neural Networks. 2009;22(8):1113–1119. [PubMed]
139. Csicsvari J, Jamieson B, Wise KD, Buzsáki G. Mechanisms of gamma oscillations in the hippocampus of the behaving rat. Neuron. 2003;37(2):311–322. [PubMed]
140. Senior TJ, Huxter JR, Allen K, O’Neill J, Csicsvari J. Gamma oscillatory firing reveals distinct populations of pyramidal cells in the CA1 region of the hippocampus. The Journal of Neuroscience. 2008;28(9):2274–2286. [PubMed]
141. Hasenstaub A, Shu Y, Haider B, Kraushaar U, Duque A, McCormick DA. Inhibitory postsynaptic potentials carry synchronized frequency information in active cortical networks. Neuron. 2005;47(3):423–435. [PubMed]
142. Atallah BV, Scanziani M. Instantaneous modulation of gamma oscillation frequency by balancing excitation with inhibition. Neuron. 2009;62(4):566–577. [PMC free article] [PubMed]
143. Coyle JT. The GABA-glutamate connection in schizophrenia: which is the proximate cause? Biochemical Pharmacology. 2004;68(8):1507–1514. [PubMed]
144. Behrens MM, Ali SS, Dao DN, et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science. 2007;318(5856):1645–1647. [PubMed]
145. Lisman JE, Coyle JT, Green RW, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends in Neurosciences. 2008;31(5):234–242. [PMC free article] [PubMed]
146. Behrens MM, Sejnowski TJ. Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex? Neuropharmacology. 2009;57(3):193–200. [PMC free article] [PubMed]
147. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. The Journal of Neuroscience. 2007;27:11496–11500. [PMC free article] [PubMed]
148. Rotaru DC, Yoshino H, Lewis DA, Ermentrout GB, Gonzalez-Burgos G. Glutamate receptor subtypes mediating synaptic activation of prefrontal cortex neurons: relevance for schizophrenia. Journal of Neuroscience. 2011;31(1):142–156. [PMC free article] [PubMed]
149. Hu H, Martina M, Jonas P. Dendritic mechanisms underlying rapid synaptic activation of fast-spiking hippocampal interneurons. Science. 2010;327(5961):52–58. [PubMed]
150. Buhl EH, Tamás G, Fisahn A. Cholinergic activation and tonic excitation induce persistent gamma oscillations in mouse somatosensory cortex in vitro. Journal of Physiology. 1998;513, part 1:117–126. [PMC free article] [PubMed]
151. Fisahn A, Pike FG, Buhl EH, Paulsen O. Cholinergic induction of network oscillations at 40 Hz in the hippocampus in vitro. Nature. 1998;394(6689):186–189. [PubMed]
152. Roopun AK, Cunningham MO, Racca C, Alter K, Traub RD, Whittington MA. Region-specific changes in gamma and beta2 rhythms in NMDA receptor dysfunction models of schizophrenia. Schizophrenia Bulletin. 2008;34(5):962–973. [PMC free article] [PubMed]
153. Mann EO, Mody I. Control of hippocampal gamma oscillation frequency by tonic inhibition and excitation of interneurons. Nature Neuroscience. 2010;13(2):205–212. [PMC free article] [PubMed]
154. Fuchs EC, Zivkovic AR, Cunningham MO, et al. Recruitment of parvalbumin-positive interneurons determines hippocampal function and associated behavior. Neuron. 2007;53(4):591–604. [PubMed]
155. Korotkova T, Fuchs EC, Ponomarenko A, von Engelhardt J, Monyer H. NMDA receptor ablation on parvalbumin-positive interneurons impairs hippocampal synchrony, spatial representations, and working memory. Neuron. 2010;68:557–569. [PubMed]
156. Traub RD, Whittington MA. Overview of normal and abnormal cortical oscillations schizophrenia. In: Traub RD, Whittington MA, editors. Cortical Oscillations in Health and Disease. New York, NY, USA: Oxford University Press; 2010. pp. 123–151.
157. Wang HX, Gao WJ. Cell type-specific development of NMDA receptors in the interneurons of rat prefrontal cortex. Neuropsychopharmacology. 2009;34(8):2028–2040. [PMC free article] [PubMed]
158. Wang HX, Gao WJ. Development of calcium-permeable AMPA receptors and their correlation with NMDA receptors in fast-spiking interneurons of rat prefrontal cortex. Journal of Physiology. 2010;588:2823–2838. [PMC free article] [PubMed]
159. Belforte JE, Zsiros V, Sklar ER, et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nature Neuroscience. 2010;13(1):76–83. [PMC free article] [PubMed]
160. Lewis DA, Levitt P. Schizophrenia as a disorder of neurodevelopment. Annual Review of Neuroscience. 2002;25:409–432. [PubMed]
161. Casey BJ, Duhoux S, Cohen MM. Adolescence: what do transmission, transition, and translation have to do with it? Neuron. 2010;67(5):749–760. [PMC free article] [PubMed]
162. Uhlhaas PJ, Roux F, Singer W, Haenschel C, Sireteanu R, Rodriguez E. The development of neural synchrony reflects late maturation and restructuring of functional networks in humans. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(24):9866–9871. [PMC free article] [PubMed]
163. Uhlhaas PJ, Roux F, Rodriguez E, Rotarska-Jagiela A, Singer W. Neural synchrony and the development of cortical networks. Trends in Cognitive Sciences. 2010;14(2):72–80. [PubMed]
164. Pike FG, Goddard RS, Suckling JM, Ganter P, Kasthuri N, Paulsen O. Distinct frequency preferences of different types of rat hippocampal neurones in response to oscillatory input currents. Journal of Physiology. 2000;529, part 1:205–213. [PMC free article] [PubMed]
165. Okaty BW, Miller MN, Sugino K, Hempel CM, Nelson SB. Transcriptional and electrophysiological maturation of neocortical fast-spiking GABAergic interneurons. The Journal of Neuroscience. 2009;29(21):7040–7052. [PMC free article] [PubMed]
166. Goldberg EM, Jeong HY, Kruglikov I, Tremblay R, Lazarenko RM, Rudy B. Rapid developmental maturation of neocortical FS cell intrinsic excitability. Cerebral Cortex. 2011;21(3):666–682. [PMC free article] [PubMed]
167. Oswald AM, Reyes AD. Development of inhibitory timescales in auditory cortex. Cerebral Cortex. 2011;21(6):1351–1361. [PMC free article] [PubMed]
168. Kuhlman SJ, Lu J, Lazarus MS, Huang ZJ. Maturation of GABAergic inhibition promotes strengthening of temporally coherent inputs among convergent pathways. PLoS Computational Biology. 2010;6(6, article e1000797) [PMC free article] [PubMed]
169. Angulo MC, Rossier J, Audinat E. Postsynaptic glutamate receptors and integrative properties of fast- spiking interneurons in the rat neocortex. Journal of Neurophysiology. 1999;82(3):1295–1302. [PubMed]
170. Spear LP. The adolescent brain and age-related behavioral manifestations. Neuroscience and Biobehavioral Reviews. 2000;24(4):417–463. [PubMed]
171. Geiger JR, Lübke J, Roth A, Frotscher M, Jonas P. Submillisecond AMPA receptor-mediated signaling at a principal neuron- interneuron synapse. Neuron. 1997;18(6):1009–1023. [PubMed]
172. Chittajallu R, Isaac JT. Emergence of cortical inhibition by coordinated sensory-driven plasticity at distinct synaptic loci. Nature Neuroscience. 2010;13(10):1240–1248. [PMC free article] [PubMed]
173. Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nature Reviews Neuroscience. 2008;9(6):437–452. [PMC free article] [PubMed]
174. Buonanno A. The neuregulin signaling pathway and schizophrenia: from genes to synapses and neural circuits. Brain Research Bulletin. 2010;83(3-4):122–131. [PMC free article] [PubMed]
175. Vullhorst D, Neddens J, Karavanova I, et al. Selective expression of ErbB4 in interneurons, but not pyramidal cells, of the rodent hippocampus. The Journal of Neuroscience. 2009;29(39):12255–12264. [PMC free article] [PubMed]
176. Wen L, Lu YS, Zhu XH, et al. Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(3):1211–1216. [PMC free article] [PubMed]
177. Fisahn A, Neddens J, Yan L, Buonanno A. Neuregulin-1 modulates hippocampal gamma oscillations: implications for schizophrenia. Cerebral Cortex. 2009;19(3):612–618. [PMC free article] [PubMed]
178. Krivosheya D, Tapia L, Levinson JN, et al. ErbB4-neuregulin signaling modulates synapse development and dendritic arborization through distinct mechanisms. Journal of Biological Chemistry. 2008;283(47):32944–32956. [PubMed]
179. Fazzari P, Paternain AV, Valiente M, et al. Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling. Nature. 2010;464(7293):1376–1380. [PubMed]
180. Ting AK, Chen Y, Wen L, et al. Neuregulin 1 promotes excitatory synapse development and function in GABAergic interneurons. The Journal of Neuroscience. 2011;31(1):15–25. [PMC free article] [PubMed]
181. Huang ZJ. Activity-dependent development of inhibitory synapses and innervation pattern: role of GABA signalling and beyond. Journal of Physiology. 2009;587(9):1881–1888. [PMC free article] [PubMed]
182. Clancy B, Darlington RB, Finlay BL. Translating developmental time across mammalian species. Neuroscience. 2001;105(1):7–17. [PubMed]
183. Bourgeois JP. Brain synaptogenesis and epigenesis. Medecine/Sciences. 2005;21(4):428–433. [PubMed]
184. Gonzalez-Burgos G, Kroener S, Zaitsev AV, et al. Functional maturation of excitatory synapses in layer 3 pyramidal neurons during postnatal development of the primate prefrontal cortex. Cerebral Cortex. 2008;18(3):626–637. [PubMed]
185. Carmignoto G, Vicini S. Activity-dependent decrease in NMDA receptor responses during development of the visual cortex. Science. 1992;258(5084):1007–1011. [PubMed]
186. Flint AC, Maisch US, Weishaupt JH, Kriegstein AR, Monyer H. NR2A subunit expression shortens NMDA receptor synaptic currents in developing neocortex. The Journal of Neuroscience. 1997;17(7):2469–2476. [PubMed]
187. Rumpel S, Hatt H, Gottmann K. Silent synapses in the developing rat visual cortex: evidence for postsynaptic expression of synaptic plasticity. The Journal of Neuroscience. 1998;18(21):8863–8874. [PubMed]
188. Erisir A, Harris JL. Decline of the critical period of visual plasticity is concurrent with the reduction of NR2B subunit of the synaptic NMDA receptor in layer 4. The Journal of Neuroscience. 2003;23(12):5208–5218. [PMC free article] [PubMed]
189. Liu XB, Murray KD, Jones EG. Switching of NMDA receptor 2A and 2B subunits at thalamic and cortical synapses during early postnatal development. The Journal of Neuroscience. 2004;24(40):8885–8895. [PubMed]
190. Fu Z, Logan SM, Vicini S. Deletion of the NR2A subunit prevents developmental changes of NMDA-mEPSCs in cultured mouse cerebellar granule neurones. Journal of Physiology. 2005;563(3):867–881. [PMC free article] [PubMed]
191. Cathala L, Holderith NB, Nusser Z, DiGregorio DA, Cull-Candy SG. Changes in synaptic structure underlie the developmental speeding of AMPA receptor-mediated EPSCs. Nature Neuroscience. 2005;8(10):1310–1318. [PubMed]
192. Olah S, Komlosi G, Szabadics J, et al. Output of neurogliaform cells to various neuron types in the human and rat cerebral corte. Frontiers in Neural Circuits. 2007;1:p. 4. [PMC free article] [PubMed]
193. Molnár G, Oláh S, Komlósi G, et al. Complex events initiated by individual spikes in the human cerebral cortex. PLoS Biology. 2008;6(9, article e222):1842–1849. [PMC free article] [PubMed]
194. Krimer LS, Zaitsev AV, Czanner G, et al. Cluster analysis-based physiological classification and morphological properties of inhibitory neurons in layers 2-3 of monkey dorsolateral prefrontal cortex. Journal of Neurophysiology. 2005;94(5):3009–3022. [PubMed]
195. Zaitsev AV, Gonzalez-Burgos G, Povysheva NV, Kröner S, Lewis DA, Krimer LS. Localization of calcium-binding proteins in physiologically and morphologically characterized interneurons of monkey dorsolateral prefrontal cortex. Cerebral Cortex. 2005;15(8):1178–1186. [PubMed]
196. Povysheva NV, Gonzalez-Burgos G, Zaitsev AV, et al. Properties of excitatory synaptic responses in fast-spiking interneurons and pyramidal cells from monkey and rat prefrontal cortex. Cerebral Cortex. 2006;16(4):541–552. [PubMed]
197. Zaitsev AV, Povysheva NV, Gonzalez-Burgos G, et al. Interneuron diversity in layers 2-3 of monkey prefrontal cortex. Cerebral Cortex. 2009;19(7):1597–1615. [PMC free article] [PubMed]
198. Hashimoto T, Nguyen QL, Rotaru D, et al. Protracted developmental trajectories of GABAA receptor alpha1 and alpha2 subunit expression in primate prefrontal cortex. Biological Psychiatry. 2009;65:1015–1023. [PMC free article] [PubMed]
199. Cruz DA, Eggan SM, Lewis DA. Postnatal development of pre- and postsynaptic GABA markers at chandelier cell connections with pyramidal neurons in monkey prefrontal cortex. Journal of Comparative Neurology. 2003;465(3):385–400. [PubMed]
200. Lund JS, Lewis DA. Local circuit neurons of developing and mature macaque prefrontal cortex: Golgi and immunocytochemical characteristics. Journal of Comparative Neurology. 1993;328(2):282–312. [PubMed]
201. Loup F, Weinmann O, Yonekawa Y, Aguzzi A, Wieser HG, Fritschy JM. A highly sensitive immunofluorescence procedure for analyzing the subcellular distribution of GABAA receptor subunits in the human brain. Journal of Histochemistry and Cytochemistry. 1998;46(10):1129–1139. [PubMed]
202. Lévi S, Logan SM, Tovar KR, Craig AM. Gephyrin is critical for glycine receptor clustering but not for the formation of functional GABAergic synapses in hippocampal neurons. The Journal of Neuroscience. 2004;24(1):207–217. [PubMed]
203. Uylings HB, Malofeeva LI, Bogolepova IN, Jacobsen AM, Amunts K, Zilles K. No postnatal doubling of number of neurons in human Broca’s areas (Brodmann areas 44 and 45)? A stereological study. Neuroscience. 2005;136(3):715–728. [PubMed]
204. Knabl J, Witschi R, Hosl K, et al. Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature. 2008;451:330–334. [PubMed]
205. Cruz DA, Lovallo EM, Stockton S, Rasband M, Lewis DA. Postnatal development of synaptic structure proteins in pyramidal neuron axon initial segments in monkey prefrontal cortex. Journal of Comparative Neurology. 2009;514(4):353–367. [PMC free article] [PubMed]
206. Bourgeois JP, Goldman-Rakic PS, Rakic P. Synaptogenesis in the prefrontal cortex of rhesus monkeys. Cerebral Cortex. 1994;4(1):78–96. [PubMed]
207. Susuki K, Rasband MN. Spectrin and ankyrin-based cytoskeletons at polarized domains in myelinated axons. Experimental Biology and Medicine. 2008;233(4):394–400. [PubMed]
208. Zhou D, Lambert S, Malen PL, Carpenter S, Boland LM, Bennett V. Ankyrin(G) is required for clustering of voltage-gated Na channels at axon initial segments and for normal action potential firing. Journal of Cell Biology. 1998;143(5):1295–1304. [PMC free article] [PubMed]
209. Anderson SA, Classey JD, Conde F, Lund JS, Lewis DA. Synchronous development of pyramidal neuron dendritic spines and parvalbumin-immunoreactive chandelier neuron axon terminals in layer III of monkey prefrontal cortex. Neuroscience. 1995;67:7–22. [PubMed]
210. Yang Y, Ogawa Y, Hedstrom KL, Rasband MN. βIV spectrin is recruited to axon initial segments and nodes of Ranvier by ankyrinG. Journal of Cell Biology. 2007;176(4):509–519. [PMC free article] [PubMed]
211. Yang Y, Lacas-Gervais S, Morest DK, Solimena M, Rasband MN. βIV spectrins are essential for membrane stability and the molecular organization of nodes of Ranvier. The Journal of Neuroscience. 2004;24(33):7230–7240. [PubMed]
212. Giedd JN, Blumenthal J, Jeffries NO, et al. Brain development during childhood and adolescence: a longitudinal MRI study. Nature Neuroscience. 1999;2(10):861–863. [PubMed]
213. Huang HS, Matevossian A, Whittle C, et al. Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. The Journal of Neuroscience. 2007;27(42):11254–11262. [PubMed]
214. Hoftman GD, Bazmi HH, Lewis DA. Developmental trajectories of transcripts regulating GABA neurotransmission in monkey prefrontal cortex. Biological Psychiatry. 2010;67:37S–38S.
215. Pinto JG, Hornby KR, Jones DG, Murphy KM. Developmental changes in GABAergic mechanisms in human visual cortex across the lifespan. Frontiers in Cellular Neuroscience. 2010;4:p. 16. [PMC free article] [PubMed]
216. Fung SJ, Webster MJ, Sivagnanasundaram S, Duncan C, Elashoff M, Weickert CS. Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. The American Journal of Psychiatry. 2010;167(12):1479–1488. [PubMed]
217. Del Rio JA, De Lecea L, Ferrer I, Soriano E. The development of parvalbumin-immunoreactivity in the neocortex of the mouse. Developmental Brain Research. 1994;81(2):247–259. [PubMed]
218. De Lecea L, Del Rio JA, Soriano E. Developmental expression of parvalbumin mRNA in the cerebral cortex and hippocampus of the rat. Molecular Brain Research. 1995;32(1):1–13. [PubMed]
219. Dzhala VI, Talos DM, Sdrulla DA, et al. NKCC1 transporter facilitates seizures in the developing brain. Nature Medicine. 2005;11(11):1205–1213. [PubMed]
220. Ben-Ari Y. Excitatory actions of GABA during development: the nature of the nurture. Nature Reviews Neuroscience. 2002;3(9):728–739. [PubMed]
221. Duncan CE, Webster MJ, Rothmond DA, Bahn S, Elashoff M, Weickert CS. Prefrontal GABA(A) receptor alpha-subunit expression in normal postnatal human development and schizophrenia. Journal of Psychiatric Research. 2010;44(10):673–681. [PubMed]
222. Fillman SG, Duncan CE, Webster MJ, Elashoff M, Weickert CS. Developmental co-regulation of the beta and gamma GABAA receptor subunits with distinct alpha subunits in the human dorsolateral prefrontal cortex. International Journal of Developmental Neuroscience. 2010;28:513–519. [PubMed]
223. Gonzalez-Burgos G, Hashimoto T, Lewis DA. Alterations of cortical GABA neurons and network oscillations in schizophrenia. Current Psychiatry Reports. 2010;12:335–344. [PMC free article] [PubMed]
224. Hashimoto T, Bazmi HH, Mirnics K, Sampson AR, Lewis DA. Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. The American Journal of Psychiatry. 2008;165(4):479–489. [PMC free article] [PubMed]
225. Bucurenciu I, Bischofberger J, Jonas P. A small number of open Ca2+ channels trigger transmitter release at a central GABAergic synapse. Nature Neuroscience. 2010;13(1):19–21. [PubMed]
226. Vreugdenhil M, Jefferys JG, Celio MR, Schwaller B. Parvalbumin-deficiency facilitates repetitive IPSCs and gamma oscillations in the hippocampus. Journal of Neurophysiology. 2003;89(3):1414–1422. [PubMed]
227. Collin T, Chat M, Lucas MG, et al. Developmental changes in parvalbumin regulate presynaptic Ca2+ signaling. The Journal of Neuroscience. 2005;25(1):96–107. [PubMed]
228. Müller M, Felmy F, Schwaller B, Schneggenburger R. Parvalbumin is a mobile presynaptic Ca2+ buffer in the calyx of held that accelerates the decay of Ca2+ and short-term facilitation. The Journal of Neuroscience. 2007;27(9):2261–2271. [PubMed]
229. Volk DW, Lewis DA. Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction. Physiology and Behavior. 2002;77(4-5):501–505. [PubMed]
230. Beneyto M, Abbott A, Hashimoto T, Lewis DA. Lamina-specific alterations in cortical GABAA receptor subunit expression in schizophrenia. Cerebral Cortex. 2011;21(5):999–1011. [PMC free article] [PubMed]
231. Möhler H. GABA(A) receptor diversity and pharmacology. Cell and Tissue Research. 2006;326(2):505–516. [PubMed]
232. Arion D, Lewis DA. Altered expression of regulators of the cortical chloride transporters NKCC1 and KCC2 in schizophrenia. Archives of General Psychiatry. 2011;68(1):21–31. [PMC free article] [PubMed]
233. Hasler G, van der Veen JW, Grillon C, Drevets WC, Shen J. Effect of acute psychological stress on prefrontal GABA concentration determined by proton magnetic resonance spectroscopy. The American Journal of Psychiatry. 2010;167(10):1226–1231. [PMC free article] [PubMed]
234. Muthukumaraswamy SD, Edden RA, Jones DK, Swettenham JB, Singh KD. Resting GABA concentration predicts peak gamma frequency and fMRI amplitude in response to visual stimulation in humans. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(20):8356–8361. [PMC free article] [PubMed]
235. Edden RA, Muthukumaraswamy SD, Freeman TC, Singh KD. Orientation discrimination performance is predicted by GABA concentration and gamma oscillation frequency in human primary visual cortex. The Journal of Neuroscience. 2009;29(50):15721–15726. [PubMed]
236. Tayoshi S, Nakataki M, Sumitani S, et al. GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study. Schizophrenia Research. 2010;117(1):83–91. [PubMed]
237. Goto N, Yoshimura R, Moriya J, et al. Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study. Schizophrenia Research. 2009;112:192–193. [PubMed]
238. Yoon JH, Maddock RJ, Rokem A, et al. GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. The Journal of Neuroscience. 2010;30(10):3777–3781. [PMC free article] [PubMed]
239. Goto N, Yoshimura R, Kakeda S, et al. No alterations of brain GABA after 6 months of treatment with atypical antipsychotic drugs in early-stage first-episode schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2010;34(8):1480–1483. [PubMed]
240. Öngür D, Prescot AP, McCarthy J, Cohen BM, Renshaw PF. Elevated gamma-aminobutyric acid levels in chronic schizophrenia. Biological Psychiatry. 2010;68:667–670. [PMC free article] [PubMed]
241. Lewis DA, González-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology. 2008;33(1):141–165. [PubMed]
242. Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Archives of General Psychiatry. 2000;57:237–245. [PubMed]
243. Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA. GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. The American Journal of Psychiatry. 2001;158(2):256–265. [PubMed]
244. Marenco S, Savostyanova AA, van der Veen JW, et al. Genetic modulation of GABA levels in the anterior cingulate cortex by GAD1 and COMT. Neuropsychopharmacology. 2010;35(8):1708–1717. [PMC free article] [PubMed]
245. Insel TR. Rethinking schizophrenia. Nature. 2010;468(7321):187–193. [PubMed]
246. Lodge DJ, Behrens MM, Grace AA. A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. The Journal of Neuroscience. 2009;29(8):2344–2354. [PMC free article] [PubMed]
247. Enomoto T, Tse MT, Floresco SB. Reducing prefrontal gamma-aminobutyric acid activity induces cognitive, behavioral, and dopaminergic abnormalities that resemble schizophrenia. Biological Psychiatry. 2011;69(5):432–441. [PubMed]
248. Gruber AJ, Calhoon GG, Shusterman I, Schoenbaum G, Roesch MR, O’Donnell P. More is less: a disinhibited prefrontal cortex impairs cognitive flexibility. The Journal of Neuroscience. 2010;30(50):17102–17110. [PMC free article] [PubMed]
249. Ahn K, Gil R, Seibyl J, Sewell RA, D’Souza DC. Probing GABA receptor function in schizophrenia with iomazenil. Neuropsychopharmacology. 2011;36:677–683. [PMC free article] [PubMed]
250. Lewis DA, Cho RY, Carter CS, et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. The American Journal of Psychiatry. 2008;165(12):1585–1593. [PMC free article] [PubMed]
251. Buchanan RW, Keefe RS, Lieberman JA, et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biological Psychiatry. 2011;69(5):442–449. [PMC free article] [PubMed]
252. Loup F, Wieser HG, Yonekawa Y, Aguzzi A, Fritschy JM. Selective alterations in GABAA receptor subtypes in human temporal lobe epilepsy. The Journal of Neuroscience. 2000;20(14):5401–5419. [PubMed]
253. Ramerstorfer J, Furtmuller T, Sarto-Jackson I, Varagic Z, Sieghart W, Ernst M. The GABAA receptor {alpha}+{beta}- interface: a novel target for subtype selective drugs. The Journal of Neuroscience. 2011;31:870–877. [PMC free article] [PubMed]
254. Fell J, Axmacher N. The role of phase synchronization in memory processes. Nature Reviews Neuroscience. 2011;12:105–118. [PubMed]
255. Eack SM, Pogue-Geile MF, Greenwald DP, Hogarty SS, Keshavan MS. Mechanisms of functional improvement in a 2-year trial of cognitive enhancement therapy for early schizophrenia. Psychological Medicine. 2010:1–9. [PMC free article] [PubMed]
256. DeRubeis RJ, Siegle GJ, Hollon SD. Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms. Nature Reviews Neuroscience. 2008;9(10):788–796. [PMC free article] [PubMed]

Articles from Neural Plasticity are provided here courtesy of Hindawi Publishing Corporation
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...